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ABSTRACT
Cardiac dysfunction is one of the largest obstacles to effective cancer treatment. Not
only do a growing number of cancer patients have significant cardiovascular risk factors at
the time of diagnosis, but a number of targeted therapies can themselves cause cardiac
dysfunction. These newer treatment options are also increasingly effective, placing a
growing emphasis on post-cancer quality of life. In some instances, a patient may outlive his
or her cancer only to succumb to heart failure in as little as five years. One such targeted
therapy is the small molecular receptor tyrosine kinase sunitinib. Sunitinib was developed in
the early 2000’s as part of a wave of antiangiogenic drugs that target the vascular
endothelial growth factor receptors and platelet-derived growth factor receptors.
Unfortunately, up to 47% of patients treated with sunitinib develop severe hypertension and
approximately 20% develop cardiac dysfunction. The aim of my dissertation is therefore
twofold: First, to identify the mechanism of sunitinib-induced cardiotoxicity in order to
develop strategies to prevent clinical cardiotoxicity and, secondly, to use this mechanistic
insight as a discovery platform to identify new targets for the treatment of human heart
failure. My work led to the discovery that coronary microvascular pericytes are a primary
target of sunitinib. Furthermore, co-treatment with thalidomide can protect from sunitinibinduced cardiac dysfunction without altering the antitumor effect of the drug. Examination of
sunitinib-induced metabolic changes revealed that sunitinib treatment leads to a profound
increase in glucose uptake in the heart and induction of the M2 isoform of pyruvate kinase.
Collectively, my work suggests that vessel normalization and the Warburg Effect may be
novel targets for the treatment of human heart failure.
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LAY SUMMARY
When one thinks of the side effects of chemotherapy, hair loss and nausea
commonly come to mind. However, a much less recognized—yet grave—side effect of
certain chemotherapies is heart failure. This is because newer treatment options have vastly
improved survival, making post-cancer quality of life much more relevant. The development
of cardiac dysfunction while receiving cancer treatment is exacerbated by the fact that a
growing number of patients have significant cardiovascular risk factors—such as obesity,
diabetes or smoking—at the time of diagnosis. Nonetheless, a patient may outlive his or her
cancer only to succumb to heart failure in as little as five years. Sunitinib is one such
chemotherapy. Primarily used to inhibit blood vessel growth in tumors, sunitinib causes a
severe increase in blood pressure in up to 47% of patients and causes cardiac dysfunction
in another 20% of patients. The aim of my dissertation is therefore twofold: First, to develop
strategies to prevent heart failure in patients receiving sunitinib and, secondly, to use what I
learn about how sunitinib affects the heart to identify new strategies to treat human heart
failure. My work led to the discovery that sunitinib disrupts the stability of blood vessels in
the heart. Furthermore, this vascular instability can be prevented by co-treatment with the
drug thalidomide. Further work revealed that sunitinib treatment leads to increased uptake of
sugar by the heart and alters the way it is broken down into fuel. My results suggest that
these changes may lead to a thickening of the walls of the heart and subsequent heart
failure. Collectively, my work demonstrates that blood vessel stability and the utilization of
sugar may be novel targets for the treatment of human heart failure.

viii

TABLE OF CONTENTS
Approval Page………………………………………………………………………………………....i
Title Page……………………………………………………………………….……………………..ii
Dedication………………………………………………………………….…………………..……..iii
Acknowledgements………………………………………………………….………………………iv
Abstract……………………………………………………………………………………………….vi
Lay Abstract……………………………………………………………………………….…………vii
Table of Contents……………………………………………………………………….…………..viii
Abbreviations………………………………………………………………………………….…....xiv
List of Tables…………………………………………………………………………………...…..xvii
List of Figures……………………………………………………………………………….……..xviii
Chapter 1: Introduction………………………………………………………………………………1
1.1 Cardiotoxicity of Chemotherapeutic Agents……………………………………….…2
1.2 Classes of Cardiotoxic Agents…………………………………………………………6
1.2.1

Anthracyclines………………………………………………………………6

1.2.2

Her2/neu Inhibitors…………………………………………………………7

1.2.3

Receptor tyrosine Kinase Inhibitors……………………………………...7

1.3 Current Methods of Diagnosis and Treatment……………………………………….8
1.4 Sunitinib…………………………………………………………………………………..9
1.4.1

Discovery and Development………………………………………………9

1.4.2

Clinical Incidence of Cardiotoxicity……………………………………..11
ix

1.4.3

Proposed Molecular Mechanisms of Cardiotoxicity……………..……16

1.5 Cardiotoxicity as a Discovery Platform…………………………………………..….21
Chapter 2: Materials and Methods……………………………………………………..…………24
2.1 Materials………………………………………………………………………..………25
2.1.1 Animals……………………………………………………………….……...25
2.1.2 Human Heart Muscle Samples……………………………………………25
2.1.3 Reagents…………………………………………………………………….26
2.2 Methods…………………………………………………………………………………26
2.2.1 Assessment of Cardiac Function……………………………………….…26
2.2.1.1 Cardiac Magnetic Resonance Imaging………………..………26
2.2.1.2 Coronary Flow Reserve…………………………………………27
2.2.1.3 Mean Arterial Pressure………………………………………….28
2.2.1.4 Cardiac Contractile Reserve (dP/dtmax) ……………………….29
2.2.1.5 Wire Myography of Isolated Aortic Rings……………………..32
2.2.2 Hyperinsulinemic Euglycemic Clamp……………………………………..32
2.2.3 Isolated Cells………………………………………………………………..33
2.2.3.1 In vitro Cell Proliferation (MTT Assay)…………………………33
2.2.3.1 Neonatal Rat Ventricular Myocytes (NRVMs)………………...34
2.2.3.2 Adult Mouse Cardiomyocytes……………………………..……35
x

2.2.4 Tissue Collection and Preservation…………………………………….…37
2.2.4.1 Protein Isolation and Quantification……………………………37
2.2.4.2 Nuclear Fractionation……………………………………………38
2.2.5 Histology and Immunohistochemistry…………………………………….38
2.2.5.1 Hematoxylin and Eosin (H&E) Staining……………………….39
2.2.5.2. Masson Trichrome Staining……………………………………40
2.2.5.3 Periodic Acid Schiff (PAS) Staining……………………………40
2.2.5.4 Scanning electron microscopy………………………………….41
2.2.5.5. Immunofluorescence and confocal microscopy……………..41
2.2.5.6 Vessel tortuosity………………………………………………….42
2.2.6 SDS-PAGE and Western Blotting…………………………………………42
2.2.7 Analysis of Gene Expression……………………………………………...45
2.2.7.1 Total RNA Isolation and Quantification………………………..45
2.2.7.2 Quantitative Real Time Polymerase Chain Reaction………..46
2.2.7.3. Restriction Enzyme Digest of PKM2 PCR Product………….48
2.2.7.4. Gene Expression Microarray…………………………………..49
2.2.8 Enzyme Activity Assays …………………………………………………...53
2.2.8.1. Lactate Dehydrogenase Activity……………………………….54

xi

2.2.8.2. Pyruvate Kinase Activity………………………………………..54
2.3 Statistical Analysis……………………………………………………………………..54
Chapter 3: Microvascular Pericytes as a Primary Target of Sunitinib Cardiotoxicity………..55
3.1 Introduction……………………………………………………………………………..56
3.1.1. Regulation of myocardial blood flow……………………………………..56
3.1.2. Microvascular Pericytes…………………………………………………...61
3.1.2.1 PDGF-B and PDGFRβ…………………………………………..65
3.1.2.2 Angiopoietin-1/Tie2………………………………………………66
3.1.2.3 Transforming growth factor beta……………………………….68
3.1.3. Strategies to increase pericyte coverage and vessel normalization….68
3.1.3.1. Inhibition of VEGF-A……………………………………………69
3.1.3.2. Thalidomide……………………………………………………...69
3.2 Results………………………………………………………………………………….72
3.2.1 Sunitinib induces cardiomyocyte hypertrophy. ………………………….72
3.2.2 Sunitinib-induced cardiac contractile dysfunction is associated with
coronary microvascular dysfunction. ……………………………………………72
3.2.3. Sunitinib treatment results in reduced vascular reactivity. ……………75
3.2.4. Sunitinib treatment leads to loss of microvascular pericytes and
microvascular abnormalities. …………………………………………………….77

xii

3.2.5. Cardiac pericyte loss is also observed with the structurally distinct
PDGFRβ inhibitor, CP-673,451. ………………………………………………...79
3.2.6. Pericyte loss is not a general feature of cardiotoxicity. ………………..83
3.2.7. Co-treatment with thalidomide ameliorates sunitinib-induced contractile
dysfunction and pericyte loss. …………………………………………………...83
3.2.8. Thalidomide does not alter the anti-tumor capability of sunitinib.…….86
4. Discussion………………………………………………………………………………..89
Chapter 4: Altered Glucose Metabolism and a PKM2 Signature in the Failing Heart……….93
4.1 Introduction……………………………………………………………………………..94
4.1.1 Sunitinib lowers blood glucose levels in patients. ………………………94
4.1.2 Increased glucose metabolism and induction of the fetal gene program
in the failing heart. ………………………………………………………………..95
4.2 Results…………………………………………………………………………………97
4.2.1. Sunitinib treatment results in increased insulin sensitivity. …………...97
4.2.2. Sunitinib treatment results in increased glycolysis and activation of the
fetal gene program. ……………………………………………………………….98
4.2.3. Glucose is redirected into secondary pathways of metabolism……..101
4.2.4. Sunitinib treatment leads to induction of PKM2. ……………………...103
4.2.5. Sunitinib treatment leads to activation of Hif1α and c-myc. …………105
4.2.6. Hif1α activation results in PKM2 induction in the heart. ……………..108
xiii

4.2.7. PKM2 is induced in the failing human heart. ………….………………108
4.3 Discussion…………………………………………………………………………….112
Chapter 5. Concluding Remarks and Future Directions. ……………………………………..117
5.1 Summary of findings…………………………………………………………………118
5.2 Does pericyte loss result in myocardial hypoxia? ………………………………..119
5.3 Sunitinib as an insulin sensitizing agent…………………………………………...123
5.4. Why do only a fraction of sunitinib-treated patients develop cardiac
dysfunction?.............................................................................................................125
5.5. Future Directions…………………………………………………………………….126
References…………………………………………………………………………………………132
Vita………………………………………………………………………………………………….164

xiv

ABBREVIATIONS
2DG

[U-14C]-2-deoxyglucose

ACC

acetyl-CoA carboxylase

ACE

angiotensin converting enzyme

ACM

adult cardiomyocytes

Alk

activin receptor-like kinase

AMPK

AMP-activation protein kinase

ANF

atrial natriuretic factor

CCTAE

Common Criteria for Adverse Events

CFR

coronary flow reserve

CHF

congestive heart failure

CRBN

cereblon

DMOG

dimethyloxalylglycine

dP/dtmax

maximum developed pressure in the left ventricle over time

ECG

electrocardiogram

EDV

end-diastolic volume

EDPVR

end-systolic pressure volume relation

eNOS

endothelial nitric oxide synthase

ESV

end-systolic volume

FDG

2-deoxy-2-[18F]fluoro-D-glucose

FLT3

fms-related tyrosine kinase 3

G6P

glucose 6-phosphate

GAPDH

glyceraldehyde 3-phosphate dehydrogenase

GDR

glucose disposal rate

GIST

gastrointestinal stromal tumors

GLUT1

glucose transporter type 1
xv

GLUT4

glucose transporter type 4

H&E

hematoxylin and eosin

Hif1α

hypoxia-inducible factor 1 alpha

hnRNP

heterogeneous nuclear ribonucleoproteins

INFα

interferon alpha

LC

lumped constant

LDH

lactate dehydrogenase

LVAD

left ventricular assist device

LVEF

left-ventricular ejection fraction

MAP

mean arterial pressure

MHC

myosin heavy chain

mRCC

metastatic renal cell carcinoma

MRI

magnetic resonance imaging

NG2

neural/glial 2

NO

nitric oxide

NRVM

neonatal rat ventricular myocytes

O-GlcNAc

O-Linked β-N-acetylglucosamine

ORR

objective response rate

PAS

Periodic Acid Schiff

PDGFRβ

platelet-derived growth factor receptor beta

PDK

pyruvate dehydrogenase kinase

PKM1

pyruvate kinase muscle type 1

PKM2

pyruvate kinase muscle type 2

PTB

polypyrimidine tract-binding protein

PV

pressure-volume

RSK

ribosomal S6 kinase
xvi

RTKIs

receptor tyrosine kinase inhibitors

SEM

standard error of the mean

TAF

tumor angiogenesis factor

TK

thymidine kinase

TNFα

tumor necrosis factor alpha

Top2

topoisomerase II

VEGF

vascular endothelial growth factor

VHL

von Hippel-Lindau

vSMC

vascular smooth muscle cell

xvii

LIST OF TABLES
Chapter 1. Introduction
Table 1.1

Classification of Clinical Trials……………………………………………………..5

Table 1.2

The National Cancer Institute’s Common Terminology Criteria for Adverse
Events………………………………………………………………………………12

Chapter 2. Materials and Methods
Table 2.1

Antibodies Used for Western Blotting……..…………………………………….43

Table 2.2

Primer and Probe Sequences for PCR/qPCR………………………………….50

xviii

LIST OF FIGURES

Chapter 1. Introduction
Figure 1.1

New York Heart Association Classification of Heart Failure……………………4

Figure 1.2

Selectivity profiles of receptor tyrosine kinase inhibitors……………………...18

Figure 1.3

Sunitinib-induced mitochondrial structural abnormalities……………………..19

Figure 1.4

Cardiotoxicity as a Discovery Platform………………………………………….23

Chapter 2. Materials and Methods
Figure 2.1

Left-ventricular Pressure-Volume Loops……………………………………....31

Figure 2.2

Analysis of the PKM splicing by restriction enzyme digestion……………….52

Chapter 3. Microvascular Pericytes as a Primary Target of Sunitinib Cardiotoxicity
Figure 3.1.1

Resistance to flow is conferred by the cardiac microvasculature……………58

Figure 3.1.2

Oxygen consumption by the heart and other organs…………………….……59

Figure 3.1.3

Integrated regulation of myocardial blood flow…………………………………60

Figure 3.1.4

Vascular pericyte coverage and pericyte anatomy…………………………….64

Figure 3.1.5

Signaling pathways mediating pericyte-endothelial cell interactions………...67

Figure 3.1.6

CRBN is the primary target of thalidomide teratogenicity………………….….70

Figure 3.2.1

Sunitinib increases cardiomyocyte cross-sectional area despite no evidence
of increased heart size……………………………………………………………73

Figure 3.2.2

Sunitinib treatment leads to contractile and microvascular dysfunction……..74

Figure 3.2.3

Sunitinib is associated with decreased vascular reactivity……………………76

Figure 3.2.4

Sunitinib does not affect large-vessel reactivity………………………………..78

Figure 3.2.5

Sunitinib treatment induces loss of microvascular pericytes………………….80

Figure 3.2.6

Pericyte loss leads to microvascular abnormalities……………………………81
xix

Figure 3.2.7

Coronary microvascular dysfunction and pericyte loss are recapitulated with
the structurally distinct PDGFRβ inhibitor, CP-673451………………………..82

Figure 3.2.8

Doxorubicin treatment does not cause pericyte loss…………………………..84

Figure 3.2.9

Sunitinib-induced pericyte death is rescued by thalidomide in vitro…………85

Figure 3.2.10 Co-treatment with thalidomide prevents sunitinib-induced cardiovascular
dysfunction and pericyte loss…………………………………………………….87
Figure 3.2.11 Co-treatment with thalidomide does not alter the anti-tumor capability of
sunitinib……………………………………………………………………………..88
Figure 3.2.12 Microarray analysis of hearts from mice treated with sunitinib or vehicle for 3
or 7 days……………………………………………………………………………92

Chapter 4. Altered Glucose Metabolism and a PKM2 Signature in the Failing Heart
Figure 4.2.1

Sunitinib increases systemic insulin sensitivity. ……………………………….99

Figure 4.2.2

Hyperinsulinemic euglycemic clamp procedure………………………………100

Figure 4.2.3

Sunitinib treatment increases glycolysis in the heart. ……………………….102

Figure 4.2.4

Glucose is redirected into secondary pathways of glucose metabolism…..104

Figure 4.2.5

Sunitinib treatment induces the M2 isoform of pyruvate kinase…………….106

Figure 4.2.6

Sunitinib treatments results in the activation of Hif1α and c-myc.………….107

Figure 4.2.7

Hif1α activation results in PKM2 induction in the heart……………………...109

Figure 4.2.8

Induction of PKM2 in the failing human heart…………………………………111

Figure 4.2.9

Summary………………………………………………………………………….116

Chapter 5. Concluding Remarks and Future Directions.
Figure 5.1.

The Krogh cylinder model of an oxygen pressure field………………………122

Figure 5.2.

The Warburg Effect in cancer cells…………………………………………….126

Figure 5.3

Summary of findings……………………………………………………………..131
xx

Chapter 1
INTRODUCTION
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1. Introduction
This dissertation addresses structural, functional and metabolic features of cardiotoxicity
of the chemotherapeutic receptor tyrosine kinase inhibitor, sunitinib. Using this compound as
a discovery platform for cellular mechanisms of heart failure my work has also resulted in
new insights into microvascular stability and metabolic features of the failing human heart.

1.1 Cardiotoxicity of Chemotherapeutic Agents
Cardiotoxicity is a frequent consequence of cancer chemotherapy. However, a
suitable definition of the term is lacking. The term cardiotoxicity includes direct effects on the
myocardium, myocardial ischemia, arrhythmias, thromboembolisms, inflammation of the
myocardium (myocarditis), and pericardium (pericarditis) as well as alterations in
hemodynamic parameters such as hypertension, acute coronary syndrome, and coronary
vasospasms. These effects can manifest acutely during treatment or occur many years after
treatment as a result of undiagnosed or subclinical cardiovascular dysfunction. Although
likely driven by vastly different mechanisms, the management of chemotherapy-induced
cardiotoxicity is no different from the management of heart failure in general. For instance,
there are no established guidelines for the specific management of chemotherapy-induced
cardiotoxicity. Physicians rely on the New York Heart Association Functional Classification
and on standard modes of treatment (e.g. beta-blockers, ACE inhibitors, and calcium
channel blockers) (Figure 1.1).
Building on previous work by Michael Schneider on c-myc signaling in the failing
heart, Hoshijima and Chien detailed the strong parallels between signaling pathways that
drive cancer growth and cardiac hypertrophy (Cheng and Force, 2010; Hoshijima and
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Chien, 2002; Mulvagh et al., 1988) Based on this reasoning it should come as no surprise
that many chemotherapeutics are also toxic to the heart.
Cardiotoxicity due to cancer chemotherapeutics is not a new phenomenon. The
cardiotoxic effects of Adriamycin® (doxorubicin), a general DNA intercalating agent, were
described even before the drug gained FDA approval in 1974. However, it was thought that
with the development of more targeted therapies, the prevalence of cardiotoxicity would
diminish. It was therefore a surprise when significant cardiotoxicities were identified with
modern agents. Cardio-Oncology (or Onco-Cardiology depending on the source) has
emerged as a new discipline with a focus on patients who develop heart failure while
undergoing cancer treatment. The primary reason for this new subspecialty is simple: along
with improving survival rates comes an increased focus on post-cancer quality of life. This is
accompanied by soaring rates of cardiovascular disease, diabetes and obesity in the
general population, significantly increasing the risk of a cancer patient developing
cardiovascular dysfunction while on treatment. Outside of major cancer treatment centers,
the underlying cardiac dysfunction is not often recognized until much later, owing to the fact
that common signs of heart failure: fatigue, dyspnea and even cachexia, are commonly
present in the cancer patient. New drugs may also not carry adequate warnings that would
aid the oncologist in recognizing symptoms..
Cardiotoxicity is often not wholly predicted by preclinical and clinical trials. This is
primarily because patients with existing cardiovascular disease, or those with risk factors
such as hypertension or coronary artery disease, are often excluded from early trials.
Additionally, routine cardiac monitoring and identification of cardiovascular endpoints are
rarely part of the trial protocol. The exception is when there is precedent of cardiotoxicity in

3

Figure 1.1

Figure 1.1. New York Heart Association Classification of Heart Failure.
[Source: American Heart Association. “Classes of Heart Failure.” 2014.
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-ofHeart-Failure_UCM_306328_Article.jsp
_306328_Article.jsp.]
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Table 1.1.
Phase
Phase I

Phase II

Phase III

New Drug
Review by FDA

Phase IV

Objective
Safety

Effectiveness

Safety and
Effectiveness

Approval

Continued
safety

Goals
• 20-80 healthy volunteers
•

Determine frequent side effects

•

Drug metabolism and excretion

•

100’s of patients

•

Determine if the drug works for a certain
disease or condition compared to standard
treatment/placebo

•

Safety and side effects continue to be
monitored

•

1000’s of patients

•

Studied in different populations at different
doses

•

Study uses of the drug in combination with
other drugs

•

Evaluate the quality of the data

•

Determine labeling and marketing

•

FDA will inspect facilities where drug will be
manufactured

•

Monitor post-marketing safety in the larger
population

•

Sponsor is required to submit periodic safety
updates to the FDA.

Table 1.1. Classification of Clinical Trials. Clinical trials are stratified based on the goal of
the study with drug safety always being the primary concern. [Source: “US Food and Drug
Administration Drug Approval Process.” Food and Drug Administration website
www.fda.gov.]
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similar drugs in a class, such as the receptor tyrosine kinase inhibitors. In this case, the FDA
may mandate assessment of cardiac function in these patients. Furthermore clinical trials—
even large phase III trials (see Table 1.1 for classification of clinical trials)—are not always
sufficiently sized to identify less common toxicities (Hawthorne, 2010). For instance if the
rate of cardiotoxicity occurs at 1 in 1000 patients and, on average, a drug is tested in a few
thousand patients before approval, there will not be a strong enough correlation to identify
the toxicity. Thus significant cardiotoxicity is often not recognized until the drug is available
to the larger population (i.e. after marketing of the new drug).
1.2 Classes of Cardiotoxic Agents
Several different types of cancer treatments cause cardiac dysfunction. Therefore, a
brief review of these agents and their effects on the heart is in order.
1.2.1 Anthracyclines
The group of anthracyclines continues to account for the majority of chemotherapyinduced cardiotoxicity. Adriamycin® (doxorubicin), a general DNA intercalating agent,
induces oxidative damage and cardiomyocyte necrosis in a dose-dependent and cumulative
manner. The mechanism of doxorubicin-induced cardiac damage is now relatively well
understood and is likely due to the generation of reactive oxygen species and
cardiomyocyte

apoptosis

(Zhou

et

al.,

2001b).

Anthracyclines

may

also

target

topoisomerase II (Top2)-dependent DNA binding in both the cardiomyocyte nucleus and
mitochondria (Zhang et al., 2012). Co-treatment with dexrazoxane, an EDTA-like iron
chelator, has proven to be an effective strategy for limiting ROS damage and cardiotoxicity
in patients receiving low-dose doxorubicin (Hasinoff et al., 2003; Swain et al., 1997).
However, dexrazoxane can interfere with the drug’s oncologic efficacy, and therefore since
2011 its use has been limited to breast cancer patients receiving high-dose doxorubicin
6

(Edvardsen and Sarvari, 2013). Nonetheless, doxorubicin remains a widely used treatment
option, particularly for pediatric lymphoma patients.
1.2.2 Her2/neu Inhibitors
Mutations in the ErbB2/Her2 receptor are common drivers of cell growth and
proliferation, most notably in ErbB2/Her2-positive breast cancer.

Patients treated with

trastuzumab (Herceptin®), a monoclonal antibody directed against the ErbB2 receptor, are
at significantly higher risk of cardiotoxicity, particularly if previously or co-treated with an
anthracycline (Hahn et al., 2014). Her2 receptors are also expressed in the heart. Our lab
has found upregulation of the receptor in the failing heart, which is partially reversible with
mechanical unloading (Uray et al., 2002). Neuregulin (NRG-1) signaling through the Her2
receptor to ErbB4 regulates an essential pro-survival pathway that mediates the heart’s
response to pressure overload stress (Sawyer et al., 2002; Zhao et al., 1998). For this
reason, angiotensin converting enzyme (ACE) inhibitors are effective in minimizing
trastuzumab cardiotoxicity (Mackey et al., 2008). Limited evidence also suggests that
moderate exercise can improve cardiac function in these patients (Jones and Alfano, 2013;
Scott et al., 2011).
1.2.3 Receptor tyrosine Kinase Inhibitors
Since Judah Folkman’s 1971 discovery of TAF (tumor angiogenesis factor), a proangiogenic factor isolated from tumor cells, the field of tumor angiogenesis, and the
development of antiangiogenic cancer therapies, has rapidly evolved (Folkman, 1971). The
first milestone was reached in 2004 when the FDA approved bevacizumab (Avastin®,
Genentech), a monoclonal antibody directed against the proagniogenic vascular endothelial
growth factor (VEGF). The success of this drug in blocking angiogenesis in several solid
tumor types—including metastatic colorectal cancer, and non-small cell lung cancer—led to
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the rapid FDA approval of two subsequent small molecule receptor tyrosine kinase inhibitors
(RTKIs): sorafenib (Nexavar®, Bayer Pharmaceuticals), in December of 2005, and sunitinib
(Sutent®, Pfizer) in January of 2006 (Rock et al., 2007). In addition to targeting the VEGFR,
these agents also target the platelet-derived growth factor receptors (PDGFRs). Both of
these agents are approved for use in metastatic renal cell carcinoma, among a group of
other highly vascularized solid tumors. Two additional small molecule RTKIs have been
developed and are now in different stages of clinical trials: axitinib (AG013736, Pfizer) and
pazopanib (Votrient®, GlaxoSmithKline).
The principle behind antiangiogenic treatment is to cut off blood supply to the tumor,
thereby inducing nutrient deprivation and limiting the potential for cell evasion and
metastasis. This is accomplished through three main mechanisms: regression of existing
vasculature, normalization of blood vessels and inhibition of the formation of new vessels
(Rini, 2007). Angiogenesis is driven primarily by the VEGF receptor, PDGFRβ, fms-related
tyrosine kinase 3 (FLT3) and the stem cell factor KIT. While FLT3 and KIT may contribute to
blood vessel growth, the antiangiogenic properties of these drugs are conferred primarily
through inhibition of the VEGFR on endothelial cells and the PDGFRβ on pericytes (Rini,
2007). While originally touted as the next revolution in cancer treatment, the promise of
antiangiogenic drugs has been somewhat disappointing. Some patients do not respond at
all whereas others rapidly develop resistance (Rapisarda and Melillo, 2012). Furthermore,
the increase in survival has been relatively modest in those who do respond.
1.3 Current Methods of Diagnosis and Treatment
Similar to non-cancer related heart failure, cardiotoxicity is usually first recognized by
a significant decrease in left-ventricular ejection fraction or fractional shortening when
assessed by echocardiography or cardiac magnetic resonance imaging. Cardiac
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arrhythmias may also be present on the electrocardiogram. Elevated circulating levels of
cardiac troponins or naturietic peptides are also indicative of cardiac damage and are also
used as biomarkers of cardiotoxicity in cancer patients (Cardinale et al., 2004; Dolci et al.,
2008). Increasingly, routine cardiac monitoring is included for patients receiving known
cardiotoxic agents, especially if there are risk factors or a family history of cardiovascular
disease.
When clinically significant cardiotoxicity is identified in a patient, an otherwise
effective cytostatic treatment must be stopped and the cardiac dysfunction addressed before
the patient either resumes treatment or switches to an alternative treatment. Management of
chemotherapy-induced cardiotoxicity is no different from treatment of standard cardiac
patients, including the usual combination of ACE inhibitors, beta-blockers and diuretics. Two
recent studies found that prophylactic treatment with the ACE inhibitor enalapril or the betablocker carvedilol helped mitigate cardiotoxicity associated with anthracycline (doxorubicin)
treatment (Lipshultz et al., 2002; Santos et al., 2002). Longer drug infusion times have also
been shown to decrease cardiotoxicity but require the use of infusion pumps and indwelling
catheters (Ewer et al., 2005). Most patients who receive proper cardiac care will recover
cardiac function. However, approximately 8% of patients who develop heart failure do not
survive past 10 years (Cheng and Force, 2010).
1.4 Sunitinib
1.4.1 Discovery and Development
Shortly after Dr. Folkman’s discovery of TAF, a number of companies developed
ATP analogs that could compete with ATP for the catalytic site on most tyrosine kinases.
This research led to the develoment of receptor tyrosine kinase inhibitors, including
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Gleevec® (imatinib), Tarceva® (erlotinib) and Sutent® (sunitinib), all of which are in current
clinical use.
Sunitinib (SU11248) was developed by Schlessinger and Ullrich who formed
SUGEN, a biotechnology company which was bought by Pharmacia and subsequently by
Pfizer (Faivre et al., 2007). After undergoing multiple iterations of the chemical due to low
solubility and high toxicity, SU11248 showed antitumor efficacy in both cell and animal
studies. Ensuing phase I trials in patients with acute myeloid leukemia and solid tumors
established a dose of 50mg per day on a 4 weeks on, 2 weeks off, cycle schedule. This was
primarily to avoid bone marrow and adrenal toxicity (Faivre et al., 2007). Phase I trials also
revealed specific efficacy for the treatment of imatinib resistant gastrointestinal stromal
tumors (GIST) and metastatic renal cell carcinoma (mRCC). Sunitinib treatment of mRCC in
Phase II trials resulted in an objective response rate (ORR) of approximately 42%. This was
far superior to the existing therapy for mRCC, interferon alpha (INFα), which had an average
ORR of less than 20% (Faivre et al., 2007). Thus sunitinib was first approved for, and is still
predominantly used for, the treatment of mRCC. Cardiotoxicity associated with sunitinib
treatment was not recognized until later Phase III trials.
Approximately 60% of mRCC tumors have mutations in the tumor suppressor, von
Hippel-Lindau (VHL) (Rini et al., 2009). VHL is an E3 ligase that under normoxic conditions
binds to hydroxylated proline residues in the alpha subunit of hypoxia inducible factor 1
alpha (Hif1α), thereby targeting it for degradation by the proteasome. When intracellular
oxygen levels fall, VHL dissociates from Hif1α, allowing it to dimerize with Hif1β and induce
transcription of a multitude of genes, including VEGF and PDGF. Accordingly, VHL
mutations in mRCC result in a strong induction of angiogenesis and highly vascularized
solid tumors. The most common clinical manifestation of VHL syndrome is angioblastoma.
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Over 1500 germline or somatic mutations have been described in VHL disease, which is an
autosomal dominant disease occurring in 1/100,000 people.
Sunitinib exhibits strongest affinity for the VEGFR followed closely by the PDGFR,
Fms-related tyrosine kinase 3 (FLT3) and KIT (Faivre et al., 2007). Sunitinib, however, is an
extremely promiscuous TKI, owing to the high conservation of the ATP binding pocket
across the kinome. In an in vitro test, sunitinib inhibited nearly 20% of all kinases tested
(Rock et al., 2007) and it is estimated that it can inhibit up to 300 different kinases (Force et
al., 2007). Nonetheless, there is a tendency to develop resistance when used as a single
treatment and there has been a push to combine sunitinib treatment with other treatments
(Faivre et al., 2007). This combination therapy may hold promise in limiting sunitinib toxicity
as the drug could be used at lower doses.
1.4.2 Clinical Incidence of Cardiotoxicity with Sunitinib.
In accordance with the National Cancer Institute’s Common Criteria for Adverse
Events (CCTAE) National Cancer (Institute, 2009), clinical trials report the incidence of
adverse events in patients receiving a new drug. Adverse events are scored on a scale of 15, with 1 being the least severe (see Table 1.2 for a description of the grading of adverse
cardiac events in clinical trials). Diarrhea, nausea, fatigue and vomiting are common with
most chemotherapeutics, but it was the high incidences of hypertension and decline in leftventricular ejection fraction (LVEF) that was most striking with sunitinib, though the reported
incidences of both vary widely (see below). This may be for several reasons including the
extent of cardiac monitoring and trial exclusion criteria.
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Table 1.2 National Cancer Institute’s Common Terminology Criteria for Adverse Cardiac Events.
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Table 1.2. National Cancer Institute’s Common Terminology Criteria for Adverse Cardiac Events. [Source: National Cancer
Institute (2009).
2009). Common Terminology Criteria for Adverse Events V4.0 H.a.H. Services, ed. (Institute, 2009)]
2009)
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In preclinical monkey studies, there was evidence of increased in arterial blood
pressure and QT intervals at high doses of sunitinib. However, the first indication of
significant hypertension with sunitinib was reported in a 2006 randomized, double blind
Phase III trial for sunitinib as a second-line treatment of imatinib-resistant GIST (Demetri et
al., 2006; Faivre et al., 2007). Of the 202 patients that received sunitinib, 18 patients (8.9%)
developed hypertension with 3 patients (6%) developing grade 3, which is defined as an
increase of greater than 20 mmHg (diastolic) or to greater than 150/100 mmHg and
requiring more than one antihypertensive medication. The major Phase III study that
supported the FDA approval of sunitinib as a second line treatment for GIST, reported
hypertension in 31 patients (15%) with 9 patients (4%) developing grade 3/4 (Rock et al.,
2007). Most relevant for my experimental work was a decline in LVEF to >50% in 11% of
patients treated with sunitinib versus 3% in the placebo group. Closely following this study, a
randomized phase III study of sunitinib versus interferon alpha as a first line treatment for
mRCC reported that 24 patients (8%) developed hypertension and 10 patients (3%)
developed a decline in LVEF of at least 10% (Motzer et al., 2007).
With a longer follow-up, Telli et al found a decline in LVEF to below normal levels
occurred in 21%, with 4% of patients experiencing a drop in LVEF of greater than 20% (Telli
et al., 2008). This was important because it suggested that a significant portion of patients
receiving sunitinib experience subclinical cardiotoxicity. In an effort to clarify the incidence of
hypertension with sunitinib, Zhu and colleagues conducted a meta-analysis of 4,999 mRCC
patients from 13 different trials and reported the incidence of hypertension to be 21.6% with
6.8% of patients developing high grade (3 or 4) hypertension (Zhu et al., 2009). Similarly, a
retrospective, multicenter analysis of 175 patients with mRCC—with a focus on adverse
cardiac events—found that 17 patients (18.9%) develop some degree of cardiac abnormality
with 12 patients (6.9%) developing grade 3 or higher left ventricular dysfunction and
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congestive heart failure (Di Lorenzo et al., 2009). Noting the high incidence of cardiotoxicity
in their own clinic, Telli and colleagues at Stanford University performed a retrospective
study of 48 patients who had received sunitinib between July 1, 2004 and July 1, 2007 in
their clinic (Telli et al., 2008). Seven patients (15%) developed symptomatic grade 3/4 heart
failure and 3 patients had persistent cardiovascular dysfunction despite discontinuation of
sunitinib and commencement of heart failure treatment. The Telli study is unique in that
these patients were treated off-protocol, meaning that no patient was excluded because of
hypertension, coronary artery disease or previous treatment with an anthracycline.
Therefore Telli’s patient population is more representative of the general population.
Collectively, the incidence of hypertension with sunitinib is approximately 20% and the
incidence of LVEF decline is between 7% and 15%.
The most quoted study of sunitinib cardiotoxicity describes a much higher incidence
of cardiotoxicity. Chu et al performed a retrospective analysis of a Phase I/II trial of 75
patients with GIST treated with sunitinib (Chu et al., 2007). Six patients (8%) developed
congestive heart failure, while 10 patients (28%) and 7 patients (19%) experienced EF
declines to >10% and >15%, respectively. The authors also report that 35 patients (47%)
had blood pressures of greater than 150/100 mmHg. In addition to vastly higher incidences
of cardiovascular toxicity compared to much of the literature, this study is notable because it
was the first attempt to evaluate the mechanism of sunitinib cardiotoxicity.
1.4.3 Proposed Mechanisms of Cardiotoxicity
While the clinical incidence of sunitinib cardiotoxicity has been extensively
documented, studies investigating the molecular mechanism tend to be descriptive, primarily
noting cardiomyocyte hypertrophy, cellular ATP depletion and apoptosis (Chu et al., 2007;
Cohen et al., 2011; French et al., 2010; Kerkela et al., 2009; Korashy et al., 2014; Will et al.,
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2008). In these studies, the mechanism is often broadly attributed to the promiscuity of the
kinase and the inhibition of a wide range of kinases. In a study using in vitro competition
binding assay, which screened 38 different compounds against 317 different kinases (~55%
of the predicted human kinome), sunitinib inhibited 57% of all kinases tested (Hasinoff et al.,
2008; Karaman et al., 2008) (Figure 1.2). This was second only to staurosporine, which is
well known as a non-selective inhibitor. A similar screen found that sunitinib inhibited up to
147 of the 242 kinases tested (Kumar et al., 2009). Beyond its primary targets (VEGFR,
PDGFR, cKIT, FLT3) sunitinib potentially inhibits the metabolic energy regulator, AMPactivated protein kinase (AMPK) and ribosomal S6 kinase (RSK) (Kerkela et al., 2009;
Laderoute et al., 2010). Consequentially, most of the investigations into the mechanism of
sunitinib cardiotoxicity have centered on these two kinases.
In their pioneering investigation of the molecular mechanism of sunitinib
cardiotoxicity, Chu and colleagues obtained endomyocardial biopsies from two patients that
had developed left ventricular dysfunction and congestive heart failure while on sunitinib
(Chu et al., 2007). Not only was there evidence of cardiomyocyte hypertrophy, but there was
also aberrantly shaped and swollen mitochondria with effaced cristae and membrane
“whorls” (Figure 1.3), though it has been suggested this is a freezing artifact (Dr. Michael
Ewer, MD Anderson Cancer Center, personal communication). The same group
demonstrated aberrantly shaped mitochondria in mice treated with sunitinib at 40mg/kg for
21 days. Nonetheless, neonatal rat ventricular myocytes treated with sunitinib at clinically
relevant concentrations (1uM) displayed increased apoptosis, as evidenced by cytochrome
c release and caspase 9 activation (Chu et al., 2007). As a follow-up to this paper, the same
group treated mice for 5 weeks at a dose of 25mg/kg (Kerkela et al., 2009). Histological
assessment of cardiomyocyte size revealed cardiomyocyte hypertrophy despite no
difference in left ventricular mass. This, the
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Figure 1.2.

Figure 1.2. Selectivity profiles of receptor tyrosine kinase inhibitors.
The sizes of the red circle represent the affinity of binding for the inhibitor to a given kinase.
The smallest circle represents a Kd of 10 µM and 1 nM for the largest circle. The tyrosine
kinases are depicted in the upper left of the graph. Sunitinib is the most non-specific kinase
inhibitor behind staurosporine. [Source: Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant,
P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., and Edeen, P.T.
(2008). A Quantitative Analysis of Kinase Inhibitor Selectivity. Nature biotechnology 26, 127132. (Karaman et al., 2008). Used with permission from the journal, license number
3583190938523.]
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Figure 1.3

Figure 1.3. Sunitinib-induced mitochondrial structural abnormalities.
Endomyocardial biopsies from two patients who developed heart failure while on sunitinib
demonstrating aberrantly shaped and swollen mitochondria with effaced cristae and
membrane “whorls.” [Source: Figure 5 from Chu, T.F., Rupnick, M.A., Kerkela, R.,
Dallabrida, S.M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., and
Desai, J. (2007). Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib. The
Lancet 370, 2011-2019. (Chu et al., 2007) Used with permission from the journal, license
number 3583200430074.]
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authors concluded, was consistent with myocyte loss, and went on to show evidence of
apoptosis in NRVMs. The authors also observed a loss of mitochondrial membrane potential
and depletion of cellular ATP content. However, mitochondrial respiration was not
measured. ATP content does not reflect the rate of ATP turnover (Taegtmeyer et al., 1985).
Consistent with the theory that sunitinib inhibits AMPK, the decline in cellular ATP levels did
not result in a corresponding activation of AMPK, as measured by phosphorylation of its
downstream target acetyl-CoA carboxylase (ACC). Furthermore, restoration of AMPK
signaling with adenoviral transfection of constitutively active AMPK reduced sunitinibinduced cell death.
Nonetheless, inhibition of AMPK as the cause of sunitinib cardiotoxicity remains a
debated issue. Activation of AMPK using the biguanide metformin did not protect from
sunitinib-induced cell death in NRVMs (Hasinoff et al., 2008). The same authors
demonstrated that ROS-mediated cell death was also not likely the cause of cardiotoxicity,
because dexrazoxane also did not prevent sunitinib-induced cell death. Pretreatment of
human induced pluripotent stem-cell derived cardiomyocytes with metformin or AICAR, a
similar AMPK activator, also did not protect from sunitinib-induced cell death (Cohen et al.,
2011). As an alternative cause of sunitinib-induced energy depletion, others have tested
whether sunitinib affects mitochondrial ATP generation. Of four small-molecule receptor
tyrosine kinase inhibitors tested (imatinib, dasatinib, sunitinib and sorafenib), only sorafenib
significantly affected respiration of isolated mitochondria from H9C2 cardiomyocytes (Will et
al., 2008). In particular, sunitinib lacked any direct mitochondrial effects. Still, others have
observed the appearance of autophagic vesicles and increased autophagic flux both in vivo
and in vitro (Knapton et al., 2013; Zhao et al., 2010). Collectively, these studies support the
notion that sunitinib treatment results in cardiac energy depletion, yet the exact mechanism
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remains to be determined. My work suggests that hypoxia plays role and is discussed in
detail in Chapter 4.
1.5 Cardiotoxicity as a Discovery Platform for Cellular Mechanisms of Heart
Failure.
Most of clinical cardiotoxicity research is centered on the development of biomarkers
for earlier identification of cardiac dysfunction as well as advancing methods of cardiac
imaging (strain-gauge echocardiography, 3D echocardiography). There is also a broad push
for increased cardiac monitoring and longer follow-up times in patients receiving known
cardiotoxic drugs. Because of the delayed cardiotoxic effects of certain chemotherapeutic
agents (Hahn et al., 2014), there has also been a call for the establishment of patient
registries to allow for easier identification of cardiotoxic therapies post-FDA approval (Cheng
and Force, 2010). Targeted delivery of therapies directly to the cancer cells through new
technologies such as nanoparticles or dual-specific antibodies may also decrease
cardiotoxicity in the future.

As discussed above, comparatively little research has

investigated the molecular mechanisms of cardiotoxicity, with the exception of doxorubicin.
Ideally, once the mechanism by which a treatment causes cardiac dysfunction is known,
adjunct therapies can be developed to protect the heart while still killing the cancer.
To this end, my first mentor Dr. Aarif Khakoo (now of AMGEN in South San
Francisco, CA) developed the concept of “cardiotoxicity as a discovery platform” (Figure
1.4). His idea was that once significant cardiotoxicity is associated with a particular new
therapy—such as sunitinib—the drug can be taken into animal studies for target
identification and mechanistic insight. This mechanistic insight can be used to identify novel
targets for the treatment of non-chemotherapy related human heart failure. I propose to
extend the concept of “cardiotoxicity as a discovery platform” to a discovery platform for the
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identification of cellular mechanisms and metabolic derangements in heart failure. Until the
work of my previous lab, PDGFRβ signaling and the presence of pericytes in the coronary
microvasculature was thought to be unimportant in the adult heart. As it will be
demonstrated in Chapter 3, PDGFRβ signaling within the pericyte is essential for the ability
of the heart to respond to stress. Increasing pericyte coverage in the failing heart may be a
novel treatment strategy for heart failure. Furthermore, as it will be demonstrated in Chapter
4, my experiments in rodents have exposed a major metabolic signaling pathway in failing
human hearts which is akin to the Warburg Effect in cancer.
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Figure 1.4.

Figure 1.4. Cardiotoxicity as a Discovery Platform. After significant cardiovascular
toxicities are identified in early clinical trials or post
post-approval
approval trails, the drug can be studies in
a mouse model for target identification and mechanistic insight. The findings can be used in
one of two ways. The first is to identify strategies to prevent and predict cardiotoxicity in the
cancer patient. The second is to identify possible novel targets for the treatment of nonnon
chemotherapy related human heart failure. [Source:
ource: Khakoo, A. “Cardiotoxicity as a
Discovery Platform.” Personal communication.
communication.]
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Chapter 2
MATERIALS and METHODS
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2.1 Materials
2.1.1 Animals
Animals were cared for according to the National Institutes of Health guidelines. All
protocols were approved by The University of Texas MD Anderson Cancer Center
Institutional Animal Care and Use Committee or the Animal Welfare Committee of The
University of Texas Health Science Center at Houston. The hyperinsulinemic euglycemic
clamp procedures were approved by the Institutional Animal Care and Use Committee of
Baylor College of Medicine (Houston, TX). All mice were of C57BL/6J background and
obtained from Jackson Labs with the exception of immunodeficient nude mice used for the
in vivo tumor xenograft experiments.
In vivo tumor xenograft experiments. Immunodeficient nude mice (NU/J) were
obtained from Jackson Laboratories. A sunitinib-sensitive, human-derived renal cell
carcinoma cell line (786-0) was obtained from Dr. Eric Jonasch at the MD Anderson Cancer
Center. Cells (107 ) were suspended in 150 ml of PBS, mixed with an equal volume of
Matrigel (BD Biosciences), and injected subcutaneously into the left flank. Mice were
euthanized when tumor volume exceeded 1500 mm3.
2.1.2 Human Heart Muscle Samples
Tissue Samples from failing hearts: Failing heart muscle samples were obtained
from patients referred to the Texas Heart Institute with advanced heart failure and implanted
with a left ventricular assist device (LVAD). Tissue from the left ventricular apex was
obtained during LVAD implantation and again at the time of device removal by Dr. O.
Howard Frazier at the Texas Heart Institute (Houston, TX). Tissue samples were
immediately freeze clamped between two aluminum blocks precooled in liquid nitrogen as
previously described by Wollenberger et al. (Wollenberger et al., 1960). Human subjects
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gave informed consent and the study protocol was approved by the Committee for the
Protection of Human Subjects of CHI St. Luke’s Health in Houston, Texas, and by The
University of Texas Medical School at Houston.
Non-failing Heart Samples: Non-failing heart samples were obtained from the apex of
the left ventricle of patients undergoing heart-lung transplantation due to pulmonary
hypertension and right-ventricular failure. Left-ventricular function was normal, as assessed
by echocardiography. A full characterization of these patients and method of tissue
harvesting has been published (Cordero-Reyes et al., 2014). This study was approved by
the Houston Methodist Hospital's Institutional Review Board.

2.1.3 Reagents
Sunitinib malate obtained from Pfizer for the pericyte experiments and purchased
from LC Laboratories (St. Louis, MO) for the metabolic experiments Dimethyloxalylglycine
(DMOG) was obtained from Tocris Bioscience (Bristol, United Kingdom). Cobalt chloride and
all other laboratory reagents were obtained from Sigma Aldrich (St. Louis, MO). Please refer
to Table 2.1 for a list of antibodies used in western immunoblotting.

2.2 Methods
2.2.1 Assessment of Cardiac Function
2.2.1.1 Cardiac Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) allows for the acquisition of precise, highresolution images of the heart. A strong magnetic field aligns the protons (mainly water
molecules) within a specimen in a single direction. Pulses of radio frequency
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electromagnetic fields are applied to alter the alignment of the protons relative to the
magnetic field. The contrast between the heart wall and the ventricle is determined by the
rate at which the excited atoms return to equilibrium. Next, a Fourier transformation converts
this signal into an image. MRI is optimized for cardiac imaging by gating the image
sequences to the electrocardiogram. This allowed for synchronization of the pulses with the
beating heart, and enabled visualization of cardiac motion and accurate assessment of
cardiac output (Epstein, 2007).
With the assistance of Dr. James Bankson and the Small Animal Imaging Facility at
M.D. Anderson Cancer Center, a protocol was developed to image mice on a Bruker 7.05-T
MR scanner (Bruker Biospin MRI, Billerica, MA). Mice were lightly anesthetized (1-2%
inhaled isoflurane) and the flow was adjusted to maintain the heart rate between 350-500
beats per minute and the rate of respiration at 30-40 breaths per minute. Mice were kept
warm (37oC) by a circulating water-filled imaging platform. Sagittal and coronal images were
first obtained to orient correctly to the left ventricle and apex of the heart. Next, six (~1mm
thick) short-axis images were obtained every 6 milliseconds with 3 milliseconds between
pulses moving from the apex to the base of the heart. The left ventricular chamber size was
determined in both systole and diastole for each of the six images by tracing the contour of
the left ventricular and using the modified Simpson’s rule for volume determination (Folland
et al., 1979). Left ventricular ejection fraction, a measure of systolic function, was defined as
LVEF = ((EDV – ESV)/EDV)*100 and averaged across the six sections.

2.2.1.2 Coronary Flow Reserve
Doppler ultrasound is an proven non-invasive method for determining blood flow in
the heart and major vessels in the mouse (Hartley et al., 2011; Hartley et al., 2008). Blood
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flow velocity is determined as the difference in wave frequency between and emitted signal
and the returning echoes from moving red blood cells. The Doppler signal is the summation
of Doppler shifted echoes from different red blood cells moving at different velocities.
Doppler shift frequency (∆f) is related to blood flow velocity (V) by the following equation:
∆f = 2fo (V / c) cosθ
Where fo is the ultrasonic frequency (20 MHz for use in mice), c is the speed of
sound in blood (∼1,540 m/s), and θ is the angle between the sound beam and the direction
of flow. When the sound beam is parallel to the direction of flow (θ is zero), the conversion
factor relating velocity to the Doppler shift is 3.75 (cm/s)/kHz at 20 MHz (Hartley et al.,
2011).
Blood flow velocity through the left descending coronary artery was measured using
a 2mm diameter 20-Mhz ultrasound probe connected to a signal processing unit
(MouseDoppler, Indus Instruments, Webster, TX). The animal was lightly anesthetized and
placed in the supine position on a warmed (37oC) procedure board containing ECG
electrodes. The ultrasound tip was stabilized and maneuvered using a micromanipulator
(model MM3-3, World Precision Instruments, Sarasota, FL) until the characteristic LAD
Doppler signal was obtained. Coronary flow velocities were determined at baseline (1%
isoflurane) and after application of a hyperemic stimulus (2.5% isoflurane). The vasodilatory
properties of isoflurane are well described and provide an advantage over adenosine in that
isoflurane has a smaller effect on heart rate (Hartley et al., 2011). The ratio of peak flow
velocities at baseline and 2.5% isoflurane is reported as the coronary flow reserve.

2.2.1.3 Mean Arterial Pressure
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Mouse blood pressure was measured non-invasively with a specialized tail pressure
transducer and occlusion cuff (CODA, Kent Scientific, Torrington, CT). This specialized cuff
directly measures blood volume in the tail (Feng et al., 2008). Non-anesthetized mice were
placed into nose cone holders and the sensor and occlusion cuff were slid onto the tail. This
was repeated on three consecutive days before the start of the experiment to allow for
acclimatization. During a given session, 10 acclimatization cycles were taken followed by 20
measurement cycles for each mouse. The system measured a total of 6 blood pressure
parameters simultaneously: systolic blood pressure, diastolic blood pressure, mean arterial
blood pressure, heart pulse rate, tail blood volume and tail blood flow (Malkoff, 2005).

2.2.1.4 Cardiac Contractile Reserve (dP/dtmax)
The ventricular pressure-volume (PV) loop relates changes in ventricular volume to
pressure throughout the cardiac cycle (Lilly and School, 1998). A PV loop begins at the
beginning of the cardiac cycle, point a, at the lower left of the loop (Figure 2.1). The point
represents the opening of the mitral valve and the beginning of ventricular filling in diastole.
A small rise in pressure is seen when travelling from point a to point b and the ventricle
stretches in accordance with the properties of passive elastic compliance. Point b is reached
when this pressure exceeds a, causing the mitral valve to close and isometric left ventricular
contraction commences. This isometric contraction occurs as the volume remains constant
as the pressure rises. When the pressure in the left ventricle surpasses the diastolic
pressure in the aorta, the aortic valve opens and the ventricle begins to empty (point c). The
pressure continues to increase until the ventricle relaxes. The curve from point c to d
represents the afterload, the pressure against which the left ventricle ejects. As the left
ventricle beings to relax (point d) the pressure in the left ventricle falls and no more blood is
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ejected from the heart. Isovolumetric relaxation will continue until the pressure in the left
ventricle drops below the pressure in the left atrium when the mitral valve opens and the
loop begins again at point a. Changes in cardiac contractility are represented by the slope of
the end-systolic pressure volume relation (EDPVR) curve. When cardiac contractility is
increased, such as by the infusion an inotropic agent such as of dobutamine (see Figure
2.1), this curve shifts upward and to the left (from 1 to 2). As a result, the stroke volume
increases and the end systolic volume decreases. When there is a defect in cardiac
contractility, such as I have observed in sunitinib-treated mice, this curve does not shift as
far, resulting in a decreased slope (Lilly and School, 1998). These experiments were
expertly performed by Vishnu Chintalgattu with assistance from me.
For the measurement of cardiac contractility, maximum pressure in the left ventricle
over time was measured by inserting a pressure sensitive catheter (1 French, Millar
Instruments, Houston, TX) into the left ventricle. Mice were deeply anesthetized with
isoflurane and fixed to a heated (37oC) procedure board containing ECG electrodes. Mice
were intubated, ventilated and a cervical incision exposed the trachea and carotid arteries.
The catheter was inserted into the left carotid artery and advanced into the left ventricle.
After stabilization of the heart rate and left ventricular pressures, pressure-volume loops
were generated using the Millar Pressure-Volume Loop System (Millar Inc. Houston TX). PV
loops were generated at baseline and with increasing concentrations of dobutamine (1, 3
and 5 mg/kg per minutes) administered through the tail vein using a syringe infusion pump.
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Figure 2.1.
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Figure 2.1. Left-ventricular Pressure-Volume Loop. A plot of the ventricular pressure as a
function of volume, over the course of the cardiac cycle. See text for a full description of the
cycle. ESPVR, end-systolic pressure-volume relation. [Source: Lilly, L.S., and School, H.M.
(1998). Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and
Faculty. (Williams & Wilkins). (Lilly and School, 1998)].
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2.2.1.5. Wire Myography of Isolated Aortic Rings
Vascular reactivity of isolated aortic rings from mice treated with sunitinib or vehicle
was performed in a blinded fashion by the lab of Dr. Nathan Bryan at The University of
Texas Institute of Molecular Medicine as previously described (Erez et al., 2011).

2.2.2 Hyperinsulinemic Euglycemic Clamp*
*This procedure was performed by Dr. Pradip Saha of the Mouse Metabolism Core
at Baylor College of Medicine.
The hyperinsulinemic euglycemic clamp procedure was first developed by DeFronzo
and colleagues in 1979 and has since become the gold standard for assessing whole-body
glucose homeostasis and insulin sensitivity in both the lab and the clinic (Defronzo et al.,
1979). During this procedure, relatively high blood insulin levels are maintained in order to
suppress hepatic gluconeogenesis such that a steady-state condition is reached where the
infusion of exogenous glucose is equivalent to the rate of whole-body glucose disposal
(GDR) (Tam et al., 2012). The GDR is directly correlated with insulin sensitivity such that a
high GDR indicates increased insulin sensitivity.
Five days before the procedure, mice were anesthetized using Nembutal (1ul/g body
weight)/ avertine (15ul/g of body weight) and a micro catheter was implanted into the jugular
vein until its tip reached to the right atrium; the catheter was tied with silk sutures at the
venotomy site. The other end of the catheter was tunneled subcutaneously around the side
of the neck to the top of the skull where it was exteriorized through skin filled with sterile
EDTA (0.45%) solution and closed the open end of the catheter using a hot metallic surface.
On the day of the procedure fasted (overnight), conscious mice were infused with insulin at
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a constant rate for 5 hours. Blood samples were collected from tail vein before infusion and
at every hour during infusion. Mice first received a primed (10uCi) and then constant rate
intravenous infusion (0.1uCi/min) of HPLC purified [3-3H] glucose for 5 hours using a syringe
infusion pump. After 60 minutes, mice were infused with 25-50% unlabeled glucose with
another infusion pump at a rate adjusted to maintain the blood glucose level at 100-140
mg/dl.

For tissue specific uptake, a 2-deoxy-D-[14C] glucose (2DG) (10uCi) bolus was

injected 45min before the end of the clamp procedure and a blood sample was collected at
the administration of 2DG. 2DG is taken up by the cell and rapidly phosphorylated by
hexokinase but not metabolized further. At the end of the procedure mice were sacrificed
and tissues were evaluated for radiolabeled 2DG content by liquid scintillation counting.
Liquid scintillation counting is the standard method to determine the radioactivity of a
sample. The energy emitted from low-energy radioisotopes is converted to light by the liquid
scintillation cocktail. This cocktail contains two main components, an organic solvent and a
scintillator(s) or fluor. The energy released from the radioactive decay excites the scintillator
which a light pulse. This light pulse is then captured by the scintillation counter’s
photomultiplier tube and counted (Bray, 1960).

2.2.3 Isolated Cells
2.2.2.1 In Vitro Cell Proliferation (MTT) Assay
Human placental pericytes (PromoCell, Heidelberg, Germany), human umbilical vein
endothelial cells (Genlantis, San Diego, CA) and human cardiac fibroblasts (Cell Systems
Corporation, Kirkland, WA) were serum starved for 6 hours followed by treatment with
sunitinib for 24 hours. Cell proliferation was measured using an MTT assay kit (Vybrant
MTT, Life Technologies, Grand Island, NY). A MTT assay is a colorimetric assay that
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measures cell proliferation by measuring the reduction of the yellow MTT dye (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to its insoluble state, which has a
purple color. This reduction requires NADH and therefore only occurs in viable, metabolically
active cells (Fotakis and Timbrell, 2006).
2.2.3.2 Neonatal Rat Ventricular Myocytes (NRVMs)
The protocol for the isolation of neonatal rat ventricular myocytes was adapted from
a method used by Dr. Diane Bick’s lab at The University of Texas Health Science Center at
Houston, Department of Pathology (Lash and Jones, 2013). All procedures were carried out
in a biological safety hood. Neonatal Sprague-Dawley rats (1-2 day old) were briefly washed
in 70% ethanol and decapitated. The heads were immediately dropped in liquid nitrogen.
The chest cavity was opened, the heart removed and placed in 1X ADS buffer (NaCl [6.8g],
KCl [0.4g], glucose [1.0g], NaH2PO4 [1.5g] MgSO4 [0.1g] HEPES [4.76g] and pH adjusted to
7.38 with HCl/NaOH in 1L total volume of double distilled water [ddH2O]) until all hearts (60
total) were collected. Hearts were rinsed once with 1X ADS buffer, halved and transferred to
25mm2 tissue culture flask (15 hearts/flask) containing 9ml of enzyme buffer (1X ADS
containing pancreatin [0.6mg/mL] and collagenase type II [73U/mL). Flasks were incubated
for 20 minutes at 37oC in a shaking water bath a total of five times. The supernatant from the
first step was discarded. The others were collected, centrifuged for 5 minutes at 300g and
the pellet resuspended in 2-3 newborn calf serum. All fractions were kept in the 37oC
incubator until the digestion was complete (no visible chunks of heart remaining).
The pooled pellets were centrifuged for 5 minutes at 300g and resuspended in 4mL
of Percoll gradient (1.082 g/mL). Percoll gradient tubes were prepared in 15ml Falcon tubes
using a 15 gauge feeding needle. Gradients were added slowly in order of increasing
density (1.05 g/mL, 1.062 g/mL, and 1.082 g/mL). Percoll gradients were centrifuged for 20
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minutes at 300g is a swing bucket rotor a room temperature. The cardiomyocytes remained
in the 1.802 g/mL layer and were collected and washed 2X with 1x ADS. After the final
wash, cardiomyocytes were re-suspended in complete media (DMEM [500mL}, BCS [50mL],
and penicillin/streptomycin [10mL of 100U/mL]). Cardiomyocytes plated at a density of 2
million cells per 60mm dish (protein) or 0.75 million cells per well in a 6-well plate (RNA).
The cell culture medium was replaced the next morning and then daily for the remainder of
the experiment. NRMVs spontaneously contract for up to 7 days in culture.

2.2.3.3 Adult Mouse Cardiomyocytes
The procedure for the isolation of adult cardiomyocytes (AMCs) was adopted from
the lab of Paul Simpson (O'connell et al., 2007). The isolation was performed under semisterile conditions; all buffers and equipment were filtered and autoclaved, respectively,
however hearts were removed and digested outside of the tissue culture hood.
Mice (6-10 weeks old) were deeply anesthetized with chloral hydrate (60mg/kg) via
intraperitoneal injection. To avoid clotting in the cardiac vessels, heparin (0.2mL of
1000U/mL) was injected intraperitoneally. The mouse was deemed fully anesthetized when
he did not respond to reflex tests (toe or tail pinch). A thoracotomy was performed and the
beating heart removed by clipping the aorta and pulmonary veins. The heart was
immediately dropped into ice-cold perfusion buffer (NaCl [120.4mM, KCl [14.7mM], KH2PO4
[0.6mM], NaHPO4 [0.6mM], MgSO4-7H2O [1.2mM], Na-HEPES [10mM], NaHCO3 [4.6mM],
taurine [30mM], BDM [10mM], and glucose [5.5mM] in cell culture grade water and pH
adjusted to 7.0 with HCl). Excess tissue (e.g. thymus) was removed and the aorta teased
from the surrounding connective tissue. The aorta was cannulated using a 22-gauge
pediatric catheter cover on a 1mL syringe containing perfusion buffer. The aorta was
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temporarily fixed onto the cannula using a microclip and the syringe was depressed to
ensure the heart inflated and there were no leaks from the aorta. The cannula was placed
on a primed, water-jacketed Langendorff-style apparatus containing warmed (37oC)
perfusion buffer and tied with silk suture. The heart was perfused in retrograde at 4
mL/minute for 4 minutes to flush and excess blood from the heart. Next, the buffer was
switched to perfusion buffer containing collagenase type II (Lot 305, Worthington
Biochemical, Lakewood, NJ) and CaCl2 [40 µM]. Once the heart became pale and soft (1620 minutes) it was cut from the cannula and immediately placed in a 60mm2 dish containing
2.5mL of stopping buffer (perfusion buffer containing 10% bovine calf serum and 100mM
CaCl2).
The heart was teased apart with forceps and pipetted up and down a few times with
a transfer pipette. The suspension was passed through a cell strainer (100µM), transferred
to a 15mL Falcon tube and centrifuged at room temperature for 3 minutes at 20g. The
supernatant was discarded and the pellet resuspended in stopping buffer containing 100µM
CaCl2. The cells were incubated at room temperature for 2 minutes and next spun again at
20g for 3 minutes. This was repeated with stopping buffer containing 400µM CaCl2 and
900µM CaCl2 to gradually restore cellular calcium levels to near physiologic concentrations.
After the final spin, cells were resuspended in plating medium (MEM [Eagle’s with Hank’s
Buffered salts] containing 10% bovine calf serum, BDM [10mM], penicillin [100U/mL] and
ATP [2mM]). Cell density was determined by counting the number of rod-shaped
cardiomyocytes. The quality of the isolation was determined by the percentage of rodshaped, compared to round-shaped cells under an inverted light microscope. At percentage
of least 50% was considered acceptable for further experimental use. Cardiomyocytes were
incubated for one hour at 37oC in 2% CO2. Plating medium was then changed to culture
medium (MEM [Eagles with Hank’s buffered salts], BSA [1mg/mL], penicillin [100U/mL, ITS
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[insulin (5ug/mL, transferring (5ug/mL) and selenium (5ng/mL)] and BDM [10mM]).
Experimental procedures began 2 hours after plating.

2.2.4 Tissue Collection and Preservation
2.2.4.1 Protein Isolation and Quantification
Previously collected tissue was removed from a -80oC freezer and immediately
placed in liquid nitrogen. Approximately 50mg of tissue was homogenized using a 2mL
Dounce homogenizer in 1mL of protein lysis buffer (KCl [20mM], HEPES [30mM], EGTA
[2.5mM], EDTA [2.5mM], β-glycerophosphate [40mM], NaF [40mM], Na4P2O7 [4mM],
glycerol (10%), Nondiet-40 [0.25%], protease inhibitor [cOmplete Mini tablets, Roche],
phosphatase inhibitor cocktail 2 and 3 [100µl each/10mL, Sigma]). Samples were
centrifuged at 14,000xg for 10 minutes at 4oC and the supernatant collected in a new tube
on ice. For cells, each plate was washed 2x with PBS and 1mL (60mm2 dish) or 100ul/well
(6-well plate) of protein lysis buffer (NaCl [150mM], HEPES [5mM, pH 7.4], EDTA [0.1mM,
pH 8.0], MgCl2 [0.1mM], DTT [0.1mM], Triton X-100 [1%], protease inhibitor [cOmplete Mini
tablets, Roche], phosphatase inhibitor cocktail 2 and 3 [100µl each/10mL, Sigma]) was used
to scrape the cells from the well. Cells were sonicated and then centrifuged at 14,000xg for
10 minutes at 4oC.
Protein concentration was quantified using a bicinchoninic acid (BCA) colorimetric
assay (Pierce, Rockford, IL) (Smith et al., 1985). Proteins in an alkaline (biuret reaction)
solution reduce Cu2+ to Cu+. Two molecules of bicinchoninic acid then chelate with each Cu+
ion to form a purple reaction product that is observed at 562nm. The amount of reduced Cu+
is proportional to the amount of protein in the sample. This reaction does not have a true
end point, the color continues to develop, but the reaction is sufficiently slow to allow for
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accurate assessment of protein concentration. Protein concentration was calculated based
on a set of BSA standards (12.5-2000 µg/µl). Protein samples were diluted (1:5-1:20) and
5µl of diluted sample was plated in triplicate in a 96-well plate. The plate was left at room
temperature for 30 minutes before being read on a plate reader.

2.2.4.2 Nuclear Fractionation
Nuclear fractionation was performed on fresh tissue on the day of sacrifice following
a protocol described by Luo et al (Luo et al., 2011). Fresh tissue or cells were homogenized
with a Dounce homogenizer in hypotonic buffer (HEPES/KOH [10mM, pH 7.5], KCl [10mM],
MgCl2 [1.5 mM], K2EDTA [1 mM], EGTA [1 mM], Igepal [0.1%], DTT [1 mM], and protease
inhibitor [cOmplete Mini tablets, Roche], phosphatase inhibitor cocktail 2 and 3 [100µl
each/10mL, Sigma]) and left on ice for 30 minutes. Intact cells were removed by
centrifugation at 53 g for 10 min. The supernatant was then centrifuged at 800xg for 10 min.
The supernatant was kept as the cytosolic fraction. The nuclear pellet was washed twice
with hypotonic buffer and lysed in isotonic buffer (hypotonic buffer plus 250 mM sucrose) by
sonication. Protein concentrations were assessed as described above.

2.2.5 Histology and Immunohistochemistry
For histological and immunological examination, hearts were removed from the mice,
rinsed in ice-cold PBS, cut on the transverse short axis near the apex of the heart. The
remaining heart was quickly frozen in liquid nitrogen. For paraffin-embedded sections, the
remaining tissue was placed in 4% paraformaldehyde or optimal cutting temperature
medium (OCT) and taken to the Histology Research Lab in the UT Department of Pathology
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and Laboratory Medicine for processing, embedding and sectioning. Both paraffinembedded and frozen tissues were sectioned at 5 microns thick slices.

2.2.5.1 Hematoxylin and Eosin (H&E) Staining
H&E staining is the most widely used stain for basic observation of tissue
morphology. Hematin, the oxidation product of hematoxylin, stains nucleic acids and other
basophilic features blue through when oxidized in situ with a strong oxidant such as sodium
iodate (Cardiff et al., 2014). Hematin binds to lysine residues of nuclear histones through a
metallic ion, usually aluminum. The tissue is oversaturated with the dye to ensure binding
and the undesirable background staining is then removed by leaching in an alcohol acid
solution. The blue is then differentiated when returned to an alkaline solution. Next, the
tissue is stained with eosin which, through a complex and poorly understood mechanism,
dyes acidic features pink.
Paraffin-embedded tissue sections were rehydrated through alcohol gradients to
distilled water. Sections were then placed in Lillie Mayer’s alum hematoxylin (Sigma Aldrich,
St. Louis, MO) for 4 minutes, rinsed in running tap water and differentiated in 0.3% acid
alcohol (350mL ethanol, 125mL ddH2O and 1.5mL concentrated hydrochloric acid) until the
background was almost colorless. Sections were rinsed in running tap water and then
Scott’s tap water substitute (2g sodium bicarbonate, 20g magnesium sulfate in 1L ddH2O) to
differentiate the blue. Next, sections were stained in Eosin-Y (Richard-Allan Scientific) for 2
minutes, dehydrated, cleared in xylene and mounted. Five random fields from the
endocardial and epicardial areas of the left ventricle were imaged at 400x using an inverted
light microscope (Motic AE2000) connected to a 3.0 megapixel camera (Moticam 3). For
measurement of cardiomyocyte cross-sectional area, round cells (40-60 per heart)
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displaying clear membrane staining and visible nuclei were traced and area calculated using
ImageJ software (Abràmoff et al., 2004).

2.2.5.2. Masson Trichrome Staining
Masson’s trichrome staining is a three color staining protocol whose primary use in
cardiology is to determine the extent of collagen deposition in the heart. Paraffin-embedded
sections were stained using a commercially available kit (Accustain Trichrome Stains, Sigma
Aldrich, St. Louis, MO). Slides were rehydrated in water and left in Bouin’s solution (Sigma
Aldrich, St Louis, MO) at room temperature overnight to achieve intense coloration of the
tissue. Slides were rinsed in running tap water until the yellow color was removed. The
nuclei were then stained in working Weigert’s Iron Hematoxylin solution (Sigma Aldrich, St.
Louis, MO) for 5 minutes and rinsed in running tap water followed by ddH2O. Next, slides
were placed in Biebrich Scarlet-Acid Fuchsin for 5 minutes to stain the cytoplasm and
muscle

fibers

red.

After

rinsing

in

ddH2O,

slides

were

placed

in

fresh

Phosphomolybdic/Phosphotungstic acid for 5-10 minutes to prepare the sections for uptake
of the Aniline blue stain. Collagen was stained blue in a Aniline blue solution and
differentiated in 1% acetic acid. Slides were rinsed, dehydrated through alcohol, cleared in
xylene and mounted.

2.2.5.3 Periodic Acid Schiff (PAS) Staining
PAS staining is used to detect glycogen in the heart. Paraffin-embedded tissues
were rehydrated to water and incubated in periodic acid (0.5%) for 5 minutes. Periodic acid
is used to oxidize the carbohydrates containing 1-2 glycols, forming aldehyde groups. The
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slides were then rinsed and placed in Schiff’s reagent (Sigma Aldrich, St. Louis, MO) for 15
minutes. The aldehyde groups react with Schiff’s reagent to form a deep pink color. Slides
were rinsed in lukewarm tap water and counterstained with Mayer’s hematoxylin. Slides
were dehydrated, cleared and mounted. Finished slides were imaged as described above.

2.2.5.4 Scanning electron microscopy
Scanning electron microscopy was performed in a blinded fashion by Dr. Kenneth
Dunner Jr. in the lab of Dr. Robert Langley at MD Anderson Cancer Center. Briefly, hearts
were fixed in 2% glutaraldehyde in a 0.1M phosphate buffer (pH 7.4) for 24 hours at 4oC and
then transported to Dr. Langley’s lab for imaging. Imaging was performed as previously
described (Higuchi et al., 2000). Images were psuedocolored in Adobe Photoshop.
Grayscale images were colored with the “hue/saturation” function and the “history brush.”

2.2.5.5. Immunofluorescence and confocal microscopy
Immunofluorescence and confocal imaging of cardiac sections for the assessment of
microvascular pericyte coverage was performed by Vishnu Chintalgattu. Hearts were fixed in
10% formalin overnight and then embedded in optimum cutting temperature (OCT) medium.
Frozen sections were incubated overnight at 4oC with anti-NG2 (1:200, Chemicon
International) or anti-CD31 (1:200 Phamingen) and then incubated at room temperature with
a fluorescently labeled secondary antibody followed by DAPI. Sections were imaged with an
LSM 510 META inverted confocal microscope (Zeiss Instruments). ImageJ was used to
quantify the NG2 and CD31 coverage area for each image.
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2.2.5.6. Vessel tortuosity
Vessel tortuosity measurements were performed by James Culver, a graduate
student in the lab of Mary Dickinson at Baylor College of Medicine, who was blinded to the
treatment groups. Isolated hearts were infused with a 70kDa tetramethylrhodamine-labeled
dextran (Invitrogen, Waltham, MA) and placed in a 1% agarose gel mold poured into a glass
bottomed tissue culture dish (MatTek, Ashland, MA). Confocal Z-stacks were acquired
beginning at the apex of the heart. Images were reconstructed and analyzed with Imaris
(Bitplane, Oxford Instruments) with custom extensions written by James Culver in MATLAB.
Vessel tortuosity was calculated for each branch (tortuosity, T, is defined as T = L/D, where
L is the total arc length along a vessel trace, and D is the total displacement between the
beginning and end of the branch).

2.2.6 SDS-PAGE and Western Blotting
Polyacrylamide gel electrophoresis (PAGE) is used to separate proteins by mass
and charge. With the addition of the denaturant sodium dodecyl sulfate (SDS), all proteins
become negatively charged and are separated solely by mass as they migrate through a
polyacrylamide gel from a negative to positively charged electrode. Gels were poured in two
steps, a lower resolving gel and an upper stacking gel. The separation of the proteins is
dependent of the percentage of acrylamide in the gel. A 10% resolving gel was used for
most proteins. In rare instances, an 8% resolving gel was used for large proteins (>100
kDa). For a 10% resolving gel 8mL of lower buffer (8mL lower buffer stock [36.3g Tris-base,
0.8g SDS, in 200mL of ddH2O, pH adjusted to 8.8], 10.5 mL acrylamide/bis [30%]. 13.4mL
ddH2O, 300µl ammonium persulfate and 30µl TEMED) was poured between two 1.5mm
Table 2.1
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Antibody

GAPDH
β-tubulin
p-PDGFRβ
PDGFRβ
NG2
O-GlcNAc
(CTD110.6)
PKM1
PKM2
Hif1α
c-myc
Histone H1
Histone H3

Molecular Manufacturer
Weight
Catalog #
(kDa)
37
Fitzgerald
10R-G109A
55
Santa Cruz
5274
190
Santa Cruz
12909-R
190
Cell Signaling
3169
270-300
Millipore
AB5320
37-250
Cell Signaling
9875
60
Sigma-Aldrich
SAB 42000094
60
Cell Signaling
4053
120
Novus
NB100-105
57-65
Cell Signaling
8492
34
Santa Cruz
10806
18
Santa Cruz
8654

1o Dilution

2o Type
(1:5000 dilution
unless noted)

1:50,000
1:1000

Mouse
1:10,000
Mouse

1:250

Rabbit

1:1000

Rabbit

1:500

Rabbit

1:1000

Rabbit

1:10,000

Rabbit

1:500

Rabbit

1:500

Mouse

1:1000

Rabbit

1:1000

Rabbit

1:1000

Goat

Table 2.1 Antibodies used for western blotting. The address of the manufacturers are as
follows: Santa Cruz Biotechnology (http://www.scbt.com/) ; Cell Signaling Technology
(http://www.cellsignal.com); Fitzgerald (http://www.fitzgerald-fii.com/); Millipore
(www.emdmillipore.com/antibodies); Novus Biologicals (www.novusbio.com).
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glass plates and allowed to solidify. A layer of isopropanol was floated on top to ensure even
transition from resolving to stacking gels. Once the gel was solidified, the isopropanol was
poured off and the stacking gel was added (2.5mL buffer stock [6g Tris-HCl, 0.4g SDS, in
100mL of ddH2O, pH adjusted to 6.8], 1.5mL acrylamide/bis [30%], 6mL ddH2O, 90µl
ammonium persulfate and 9µl TEMED). A comb was inserted and the gel was left to solidify
a room temperature.
Protein samples (8-20µg in 5X loading buffer [For 30mL, 3.48g DTT, 9mL glycerol,
6mL SDS (20%), 7.5mL 1M Tris-HCl (pH 6.0), 2mL bromophenol blue) were boiled to 10
minutes at 70oC and cooled to room temperature before loading into gels. Gels were run at
50mV in running buffer (6g Tris-base, 28.8g glycine, 1g SDS in 1L ) until the protein traveled
through the stacking gel and then turned up to 100mV for the remainder of the run.
Separated proteins were transferred to a PVDF (PolyVinyliDene Fluoride) membrane
using a wet transfer method. PVDF membranes were pre-soaked in methanol (PVDF is
highly hydrophobic, which makes it ideal for protein binding) and then soaked along with
sponges and filter paper in cold transfer buffer (100ml of 10x stock [144g Tris-base, 30g
glycine, 0.5g SDS in ddH2O [1L], 200mL methanol and 700mL ddH2O) until use. After
completion of the run, gels were soaked in transfer buffer for 10 minutes. A “sandwich” was
then prepared from the bottom (cathode side) to the top (anode side) with a sponge, filter
paper, gel, PVDF membrane, filter paper and sponge. The transfer was run in the cold room
(4oC) for either two hours at 110mV or overnight at 40mV.
Following the transfer, membranes were stained with Ponceau to ensure proper
transfer and then blocked for one hour at room temperature in 5% milk. Membranes were
incubated overnight in primary antibody (Table 2.1) with gentle rocking. Following 3, 10
minute washes in 0.4% Tween-TBS (Tris-Buffered Saline) membranes were incubated with
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a HRP (horseradish peroxidase) conjugated secondary antibody in 5% milk for one hour at
room temperature. Membranes were washed 3 x 10 minutes and then developed using
Western Blotting Luminol reagent (Denville Scientific, South Plainfield, NJ). After
developing, membranes were stripped and re-probed up to three times with stripping buffer
(6mL Tris-HCl [1M, pH 6.8], 19.2mL SDS [10%], 0.675mL β-mercaptoethanol, and 70mL
ddH20).
Protein levels were quantified using densitometry. Films were scanned in black and
white for consistent analysis and images were analyzed using the gel analysis tools in the
ImageJ software (Abràmoff et al., 2004).

2.2.7 Analysis of Gene Expression
2.2.7.1 Total RNA Isolation and Quantification
Total RNA was isolated using TRIzol Reagent (Life Technologies, Carlsbad, CA)
following the manufacturer’s protocol with slight modifications. Human RNA was isolated
using a kit per the manufacturer’s instructions (RNeasy Fibrous Tissue kit, Qiagen, USA).
No more than 20mg of tissue or cells were homogenized in 1mL of TRIzol with a Dounce
homogenizer. RNA was then extracted by adding 0.2mL of chloroform to the tube and
shaken vigorously for 2-3 minutes at room temperature. Samples were centrifuged at
12,000xg for 15 minutes at 4oC. The aqueous phase was carefully removed to a new tube.
For RNA extraction of adult cardiomyocytes, RNase-free glycogen (5µg) was added to the
tube to aid in RNA precipitation. 0.5mL of isopropanol was added to the new tubes and
samples were placed at -20oC overnight to allow for RNA precipitation. The next day,
samples were centrifuged for 10 minutes at 12,000xg. The pellet was washed one time with

45

1mL of 75% ethanol and allowed for air dry for 10 minutes. Pellets were resuspended in
RNase-free H2O (20-50µl) and incubated at 60oC for 10 minutes.
Total RNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, DE). RNA quantity was determined using the Beer-Lambert Law,
A=ECL (where A=absorbance, E=molar extinction coefficient [0.027 µg/mL/cm for single
stranded RNA], C=concentration and L=light path) (Sambrook and Russell, 2001). The
purity of the RNA was determined by the A260/280 ratio with a ratio of >1.8 accepted as pure
RNA.
RNA was reverse transcribed into cDNA in a separate reaction. 2ug of total RNA in a
total of 12.5ul was added a nuclease-free tube followed by 7.5ul of reaction mix (0.5µl
random hexamer primers [100pmol], 4µl 5x reaction buffer [Thermo Scientific], 2µl dNTPs
[10mM], and 1µl reverse transcriptase [RevertAid, Thermo Scientific]). Samples were
incubated for 10 minutes at 25oC followed by 60 minutes at 42oC. The reaction was
terminated by heating at 70oC for 10 minutes.

2.2.7.2 Quantitative Real Time Polymerase Chain Reaction (qPCR)
Most primer and TaqMan probe sets were already available in the lab. Those not
already available were designed using OligoArchitect (Sigma-Aldrich, St. Louis, MO).
Quantification was performed by multiplexing with 6-FAM (reporter) / TAMRA (quencher)
and JOE (reporter) / BHQ1 (quencher) dyes for the target and the GAPDH endogenous
control, respectively. This dye pair was chosen because the large difference in emission
maximum gives the lowest spectral overlap. ROX reference dye (Invitrogen, #12223-012)
was used as a passive reference dye to control for non-related fluctuations in the
fluorescence. The amplification of the more abundant GAPDH was limited by the primer
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concentration. This serves to spare common reagents (dNTPs, Mg2+) for amplification of the
target gene. The multiplex reaction mix was as follows:

Multiplex PCR Mix
10X PCR Buffer
dNTPs 2.5mM
MgCl2 50mM
Primers-F/R target gene (20µM)
Primers-F/R endogenous (20µM)
50X Rox Reference Dye
Probes (10µM)
Taq
DEPC H20
diluted cDNA (~1:20)

µl per Reaction (25µ)
2.5
3
2.5
1.125 ea.
0.375 ea.
0.5
0.625 ea.
0.5
4.25
5

Concentration in Reaction
1X
300nM
5mM
900nM
300nM
1X
250nM

To test for reaction efficiency, reactions were run in singleplex using a standard curve. The
standard curve consisted of cDNA serially diluted ranging from 20pg-0.2fg. The reaction mix
is as follows:

PCR Mix
10X PCR Buffer
dNTPs 2.5mM
MgCl2 50mM
Primers-F/R 20µM
50X Rox Reference
Probe 10µM
Taq
DEPC H20
diluted cDNA (~1:20)

per well (25µl)

Concentration in Reaction
2.5
1X
2.5
250nM
1.5
3mM
0.75 ea.
600nM
0.5
1X
0.25
100nM
0.5
10.75
5

The standard curve is plotted on a linear scale as CT versus the concentration of the cDNA.
The efficiency of the PCR can be determined from the slope of the standard curve using the
formula:
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Adequate efficiency was determined as having a slope between -3.58 and -3.10. The
coefficient of correlation (R2) was required to be at least 0.98.
Gene expression was analyzed using the ABI Prism® Sequence Detection System.
Transcript levels were evaluated using the comparative CT method (ΔΔCT method),
normalized to GAPDH as an endogenous control, and expressed as a fold difference from
control (Biosystems, 2008). The comparative CT method eliminates the need for a standard
curve by instead using the relative difference between the control and treated samples.
Samples were run in triplicate and average ΔCT values for each sample for both the target
gene and endogenous control was obtained through the software. All other calculations
were performed in Microsoft® Excel. A simplified example:

GAPDH

Target

∆CT

∆∆CT

Fold Difference*

Sample

Avg. CT

Avg. CT

Target – GAPDH

∆CT - (Avg. Control ∆CT)

Control 1

15.791

16.202

0.411

-0.285

1.218

Control 2

16.667

17.329

0.662

-0.034

1.023

Sample 1

16.374

15.869

-0.505

-1.201

2.298

Sample 2

16.793

17.469

0.676

-0.02

1.013

2

- ∆∆CT

*For derivation of the formula 2- ∆∆CT, see Applied Biosystem’s User Bulletin #2:
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocument
s/cms_040980.pdf

2.2.7.3. Restriction Enzyme Digest of PKM2 PCR Product
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Analysis of pyruvate kinase alternative splicing was performed as previously
described with minor changes (Clower et al., 2010). Alternative splicing of exon 9 and 10 of
the PKM gene results in two identical length isoforms, PKM1 and PKM2 (Figure 2.2). Mouse
and human primer sets were designed to amplify exons 8 through 11. cDNA products were
digested with PstI, NcoI (New England Biolabs, Ipswich, MA), both or left undigested.
Products were run on a 5% native polyacrylamide gel [12mL 5X TBE (TrisBase, Boric acid,
EDTA), 10mL 30% acrylamide/Bis solution, 38mL DDH2O, 40ul TEMED, 400ul APS] at 30V
in the cold room. The gel was post-stained with ethidium bromide [0.5ug/mL] for 20 minutes
followed by two 20 minute washes with ddH2O. Gels were imaged using a TD-1000R
BiOVision dual-light transiluminator coupled to a camera. Images were analyzed using
ImageJ.

2.2.7.4 Gene Expression Microarray
A gene expression microarray was performed by Vishnu Chintalgattu using a Mouse
Genome 430 2.0 array gene chip purchased from Affymetrix (Santa Clara, CA). RNA from
the hearts of mice treated with sunitinib or vehicle control for 3 or 7 days was used
according to the manufacturer’s protocol.
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Table 2.2. Primer and Probe Sequences for PCR and qPCR.
Gene

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

Probe (5’-3’)

m PKM (exon 8-11)

GTCTGGAGAAACAGCCAAGG

CAACATCCATGGCCAAGTT

N/A

h PKM (exon 8-11)

AGAAACAGCCAAAGGGGACT

CATTCATGGCAAAGTTCACC

N/A

m PKM1

GCTGTTTGAAGAGCTTGTGC

TTATAAGAGGCCTCCACGCT

[6fam]CCAGTCACTCCACAGACC[tam]

m PKM2

CAGAGGCTGCCATCTACCAC

TCCTCGAATAGCTGCAAGTG

[6fam]GCCCGAGAGGCAGAGGCTGCC[tam]

h PKM1

AGCTGTTTGAAGAACTTG

CTCCGTCAGAACTATCAA

[6fam]GGAGTGCGTCTTGTGTCAGAA[tam]

h PKM2

GCCATCTACCACTTGCAA

CTTGGTGAGGACGATTATG

[6fam]CGGTGCATGCGTACTCCTTA[tam]

m GAPDH

GGTCTACATGTTCCAGTA

CCCATTTGATGTTAGTGG

[hex]ATTCAACGGCACAGTCAAGGC[bhq1]

m 18S

AGCTGAAACTTAAAGGAATTG

CACGGAATCGAGAAAGAG

[hex]TATCAATCTGTCAATCCTGTCCGTGT[bhq1]

m hnRNPA1

AGGAGGTTCTAATTACATACA

GCTGAGTTCACAAATCTG

[6fam]CTGTCACTTCTCTGGCTCTCCTC[tam]

m hnRNPA2

CTGTGAAGAAGCTGTTTG

CAGGATCATGGTCATCAA

[6fam]AAGGAAGATACTGAGGAACACCACC[tam]

m PTB

GGACCAAAGTTTAGCTTTC

CCCCACAGGTATAAAATCA

[6fam]ACTCTTCCACGCCTTCCACA[tam]

m c-myc

CGACTACGACTCCGTACAGC

GTAGCGACCGCAAACATAGGA

[6fam]CAGCAGAGCGAGCTGCAGCC[tam]

m GLUT4

TTCTGACCAACTAAGGGCGG

GTTCCTCCAGCACAGGACAC

[6fam]GCTGCCTATAAACACTGGTT [tam]

mr Hif1α

GGAAGCGAAAAATGGAACATC

TCACCTGGTTGCAGTAA

[6fam]TTCCAATTCCTGCTGCTTGAAAAAGGG[tam]

m PDK4

CTTTTCTGCGGCAAGAGCTG

TTCACTAAGCGGTCAGGCAG

[6fam]GGCCAATATCCTGAAGGAGA[tam]

m Angptl4

GGGACTGCCAGGAACTCTTC

GAAGTCCACAGAGCCGTTCA

[6fam]GGGAGCGGCACAGTGGACTT[tam]

m PHD3

AGGCAATGGTGGCTTGCTAT

GACCCCTCCGTGTAACTTGG

[6fam]CACCTGTATCTACTACCTGA[tam]

mr GLUT1

CATCGTCGTTGGGATCCTTA

GAGCAGTAGAGGCCACAAGTCT [6fam]AGGTGTTCGGCTTAGACT[tam]

mr PDK1

GATCAGAAACCGGCACAATGA

AGGATGCACCCCGAAGCT

[6fam]CCATGGCCCAGGGTGTGACTGA[tam]
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mr LDHa

CGACTGCACCATGATCGTG

TCCAGATTGCATCCACTTCC

[6fam]AGGCACACTGGCGTCGCCATGCT[tam]

mr αMHC

GCAAAGGAGGCAAGAAGAAAGG TGAGGGTGGGTGGTCTTCAG

[6fam]ACAGTGTCTGCTCTCCACCGGGAA[tam]

mr βMHC

AGGGCGACCTCAACGAGAT

CAGCAGACTCTGGAGGCTCTT

[6fam]AGCTCAGCCATGCCAACCGTA[tam]

mr c-fos

GGTGCTGGATTGTATCTA

TGGTCGTTTCTAATTGGA

[6fam]CACGCTATTGCCAGGAACACAG[tam]

mr ANF

AGTGCGGTGTCCAACACAG

CTTCATCGGTCTGCTCGCT

[6fam]TCTGATGGATTTCAAGAA[tam]

Table 2.2 Primer and Probe Sequences for PCR/qPCR. Sequences are listed in the 5’ to 3’ direction. Dyes used for each probe
are denoted in brackets. Species is specified as: m, mouse; h, human’ r, rat.
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Figure 2.2.

Figure 2.2 Analysis of the PKM splicing by restriction enzyme digestion. (A) Diagram
displaying the cDNA products obtained using primers designed to amplify exon 8 through
exon 11 of the PKM gene. (B) PKM isoform expression in the H9C2 rat cardiomyoblast cell
line, isolated
solated neonatal rat ventricular myocytes (NRVMs) or isolated adult mouse
cardiomyocytes. The RT-PCR
PCR product was divided into four aliquots and left either uncut (U)
or digested with PstI (P), NcoI (N) or PstI plus NcoI (NP). (C) PKM isoform expression in the
U87 human glioblastoma cell line (as a positive control) or heart muscle samples from nonnon
failing and failing human hearts.
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2.2.8 Enzyme Activity Assays
Spectrophotometry was used to indirectly measure the rate of the appearance of a
product of an enzymatic reaction. A spectrophotometer consists of two instruments, a light
source (spectrometer) and a photometer, for capturing the light. A sample is placed in a
liquid cuvette between the two instruments such that a light beam passes through the
sample where a portion is absorbed. When light of a single wavelength passes through the
solution, there is a direct relationship (Beer’s Law) between the amount of light absorbed
and

the

concentration

of

the

reaction

product

(http://www.shimadzu.com/an/uv/support/fundamentals/structure.html):
Beer’s Law: I = Io * 10-εcl
Where I is the intensity of the light transmitted, ε is the reaction product’s absorption
coefficient, c is the concentration of the reaction product and l is the length of the light path.
Because the light path is constant, the equation can be rewritten to
I / Io = 10-εcl = T
T is the transmittance and there is a logarithmic relationship between the
transmittance and the concentration of the reaction product such that
-log T = log 1/T = εcl = Optical density (absorbance)
Enzymes were extracted from whole tissue (~100mg) in 1mL of enzyme extraction
buffer (50mM Tris-Base [pH 7.5], 100mM KCl, 5mM MgCl2, 1mM EDTA [pH 7.6], 1% Triton
X-100 and L-glutathione [153mg/50mL]) using a Dounce homogenizer. Samples were
centrifuged for 5 minutes at 4oC and the supernatant recovered in a new tube. All enzyme
activity assay protocols were adopted from Bergmeyer’s Methods of Enzymatic Analysis
(Bergmeyer, 2012).
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2.2.8.1. Lactate Dehydrogenase Activity
Lactate dehydrogenase enzyme activity was measured in a phosphate buffer (0.1M,
pH 7.0) containing pyruvate (2.5mg/mL) and NADH (10mg/mL). Activity was measured as
the change in absorbance due to the oxidation of NADH at 340nm and normalized to protein
content.

2.2.8.2. Pyruvate Kinase Activity
Pyruvate kinase activity was measured in a triethanolamine buffer (0.1M, pH 7.6)
containing phosphoenolpyruvate, tri(cyclohexylammonium) salt (3.75mg/ml in 0.05M MgSO4
/0.2M KCl buffer), ADP (30mg/mL, neutralized with KOH), NADH (10mg/mL) and LDH (from
rabbit muscle, 32U/mL). Kinase activity was measured as the change in absorbance due to
the oxidation of NADH at 340nm over the course of 12 minutes. Activity was normalized to
protein concentration.

2.3 Statistical Analysis
Except where noted, results are expressed as the mean ± the standard error of the
mean (SEM). Analysis was performed using ABI Prism Graphpad software using a twotailed unpaired Student’s t test or one-way ANOVA with a Tukey post hoc test. A P value of
> 0.05 was considered statistically significant. In general, *P < 0.05, **P < 0.01 and ***P <
0.001. P values that differ from this convention are indicated within the graph.
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Chapter 3
MICROVASCULAR PERICYTES AS A PRIMARY TARGET
OF SUNITINIB CARDIOTOXICITY

Notes
1. A considerable amount of the work presented in this chapter was performed by Vishnu
Chintalgattu, PhD (currently a Senior Scientist in Cardiovascular Research at Amgen, Inc.,
San Francisco, CA). The work is presented here with the permission of both Dr. Chintalgattu
and Dr. Aarif Khakoo
2. Some figures are recreated from Chintalgattu, V., Rees, M.L., Culver, J.C., Goel, A.,
Jiffar, T., Zhang, J., Dunner, K., Pati, S., Bankson, J.A., and Pasqualini, R. (2013). Coronary
Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity.
Science translational medicine 5, 187ra169-187ra169. (Chintalgattu et al., 2013), with
permission from the American Association for the Advancement of Science (license number
3466011035286).
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3.1. Introduction
This chapter demonstrates that a primary cause of sunitinib cardiotoxicity is loss of
coronary microvascular pericytes, resulting in coronary microvascular and cardiac contractile
dysfunction. The data presented here show that loss of PDGFRβ signaling in the pericyte is
a primary mechanism of sunitinib cardiotoxicity. Furthermore, I show that co-treatment with
thalidomide preserves microvascular and contractile dysfunction without interfering with the
anticancer efficacy of sunitinib.

3.1.1. Regulation of myocardial blood flow.
Sunitinib is foremost an inhibitor of angiogenesis and, as will be demonstrated in this
chapter, sunitinib treatment leads to a disruption of myocardial vascular stability and function
(Chintalgattu et al., 2013). Thus, a basic review of the regulation of myocardial blood flow is
warranted. For an in-depth review of the regulation of blood flow in the coronary
microcirculation, I refer to (Muller et al., 1996; Rubio and Berne, 1975).
Regulation of coronary blood flow is conceptually divided between regulation of the
larger conduit vessels (>300µm in diameter), which confer little resistance to flow, and
regulation of the smaller resistance vessels (<300µm in diameter) (Schelbert, 2010). Figure
3.1.1 depicts the decline in blood flow velocity as a function of vessel cross-sectional area.
The majority of coronary vascular resistance resides in the coronary arterioles less than
150µm in diameter (Chilian et al., 1986). It is important to note that there is considerable
heterogeneity even within the small resistance vasculature. Vascular reactivity can differ
substantially from the large to small arterioles as well as between the subendocardium—
which is uniquely subject to the extravascular compressive forces of systole—and the
subepicardium (Muller et al., 1996; Schelbert, 2010).
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In the heart, the demand for oxygen is exactly matched by supply of oxygen through
the coronaries. Unlike most other tissues, baseline extraction of oxygen is near maximal in
the heart (Figure 3.1.2) (Gorlin, 1976). Accordingly, the primary mechanism to increase
oxygen delivery to the myocardium is dilation of the small resistance vessels. At the same
time, capillary pressure must remain constant to ensure efficient delivery of oxygen and
nutrients (Muller et al., 1996). Angina pectoris—a painful tightening of the chest—occurs
when myocardial oxygen demand exceeds coronary supply (Katz, 2010). It is important to
note that oxygen delivery is also dependent on the hemoglobin content of the blood. For this
reason, angina pectoris can result from severe anemia (Katz, 2010). Regulation of coronary
vascular resistance is primarily controlled at local level, known as autoregulation, through
myocardial production of metabolites, flow-mediated endothelial cell activation, and
stimulation of the vascular smooth muscle (myogenic vasodilation) (Muller et al., 1996). The
autonomic nervous system also controls vascular tone through activation of the alpha- and
beta adrenergic receptors (Opie, 2004). The integration of signals leading to blood vessel
dilation is summarized in Figure 3.1.3.
Myocardial demand for increased oxygen is thought to be transmitted through
accumulation of adenosine, a degradation product of AMP and ADP (Schelbert, 2010).
Adenosine readily diffuses out of the cell where it binds to receptors on vascular smooth
muscle cells, leading to decreased intracellular calcium and relaxation (Lilly and School,
1998). Adenosine preferentially relaxes small arterioles compared to the larger vessels.
Kantasuka and colleges demonstrated that rapid pacing of canine hearts led to dilation of
both the large and small arterioles; however endogenous or exogenous supply of adenosine
caused dilation in only the small arterioles (Kanatsuka et al., 1989). In addition to adenosine,
other metabolic vasodilators include lactate, acetate and carbon dioxide (Katz, 2010).
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Figure 3.1.1.

Figure 3.1.1. Relation between vessel cross-sectional area and blood flow velocity.
The largest resistance to blood flow in the heart is conferred by the smallest vessels in the
heart. These vessels also account for the largest area in the heart. [Source: Rushmer, R.F.
(1976). Cardiovascular Dynamics. (W.B. Saunders Company). (Rushmer, 1976)].
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Figure 3.1.2.

Figure 3.1.2. Oxygen consumption by the heart and other organs. The heart consumes
more oxygen than any other organ at rest. Skeletal muscle can increase oxygen extraction
during exercise but cardiac muscle oxygen extraction remains constant. Cardiac oxygen
consumption per minute (qO2) is equal to the difference between the arterial and venous
percent oxygen multiplied by coronary flow. [Source: Gorlin, R. (1976). Coronary Artery
Disease. (W.B. Saunders Company). (Gorlin, 1976)].
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Figure 3.1.3.

Figure 3.1.3. Integrated regulation of myocardial blood flow. Metabolic, myogenic and
flow-dependent mechanisms act in a concerted manner to maintain proper oxygen delivery
to the myocardium. [Source: Figure 5, Muller, J.M., Davis, M.J., and Chilian, W.M. (1996).
Integrated Regulation of Pressure and Flow in the Coronary Microcirculation. Cardiovasc
Res 32, 668-678. (Muller et al., 1996)]. Reused with permission from the journal.
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In addition to of the effects of myocardial derived metabolites, microvascular tone is
dependent on endothelial-mediated release of vasoactive compounds such as nitric oxide
(NO), prostacyclin and endothelin-1. These factors are released from in endothelial cell in
response to neural stimulation (i.e. acetylcholine), or shear-stress (also known as flowmediated vasodilation). NO is the primary mechanism through which endothelial cells induce
relaxation. NO is synthesized by endothelial NO synthase (eNOS) where it diffuses to the
adjacent smooth muscle and activates guanylyl cyclase, which converts guanosine
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Increased intracellular
cGMP leads to decreased Ca2+ levels and smooth muscle cell relaxation. Antagonism of
eNOS with L-NG-nitroarginine methyl ester (L-NAME) in isolated porcine coronary
microvessels produces constriction, indicating that there is tonic release of NO in the
microvasculature (Kuo et al., 1991).
Ultimately, vascular tone is dependent on the contraction and relaxation of vascular
smooth

muscle

cells.

This

results

from

calcium-dependent

phosphorylation

and

dephosphorylation of myosin by the myosin light chain kinases (MLCK) and myosin light
chain phosphatases, respectively. The dynamics of the actin-myosin interaction and
crossbridge cycling in mediating mural cell contraction or relaxation is of indirect relation to
the work presented here and is discussed in Katz’ Physiology of the Heart or any other
physiology textbook (Katz, 2010).
While the microvasculature confers the largest resistance to flow, it is consists of
relatively little vascular smooth muscle. Instead, the structure and function of the
microvasculature is supported by pericytes, which are discussed in detail below (Armulik et
al., 2005).
3.1.2. Microvascular Pericytes
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Pericytes were first described by Carl Josef Eberth in 1871. However, their discovery
is attributed to Charles-Marie Benjamin Rouget who in 1873 described “a population of cells
closely associated with the endothelial cells of the microcirculation” (Armulik et al., 2005).
Rouget cells were subsequently named pericytes nearly 50 years later by Karl Wilhelm
Zimmermann, alluding to their perivascular location.
Despite being the second most abundant cell type in the heart (Nees et al., 2012),
evaluation of pericyte function in the heart has been limited until relatively recently. Pericytes
have now been successfully isolated from a number or organs, including the heart (Nees et
al., 2013). Due to their pluripotent nature pericytes are of particular interest in regenerative
medicine, specifically post myocardial infarction (Gómez-Gaviro et al., 2012).
Most pericytes originate from the mesenchyme (Armulik et al., 2011). However,
central nervous system and thymus pericytes are derived from the neural crest. Coronary
pericytes arise from epicardial mesothelium (Armulik et al., 2011) where they undergo
epithelial-to-mesenchymal transition, migrate into the interstitial space of the myocardium
and fully differentiate. It is known that pericytes proliferate in vitro and in the CNS and may
also differentiate from proliferating vascular smooth muscle cells (Nehls and Drenckhahn,
1993). While the developmental origin of pericytes is well studied, much less is known about
their origin and proliferation during angiogenesis in the adult.
Pericytes are difficult to define as there is no single unequivocal marker that
distinguishes them from other mesenchymal cells such as vascular smooth muscle cells and
myofibroblasts. Nor is expression of any pericyte marker stable in its expression (discussed
in more detail below). Therefore identification of pericytes relies on a combination of
morphology, location, degree of vessel coverage and protein expression patterns. Key to
their definition is that pericytes are embedded within the vascular basement membrane
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which is continuous with the endothelial basement membrane (Armulik et al., 2005). Thus,
definitive identification of pericyte requires detailed electron microscopy. Even then,
pericytes are not always embedded in the basement membrane such as during active
angiogenesis or certain disease states (Gomez et al., 2005).
Pericytes consist of a single cell body with long processes that extend the abluminal
length of multiple endothelial cells, attaching to the endothelial cells through peg-socket type
contacts (Figure 3.1.4). Pericytes also contact endothelial cells though N-cadherin based
adhesion plaques and possibly also through gap junctions (Armulik et al., 2005; Cuevas et
al., 1984). Secondary processes extend perpendicular to the primary processes, circling
around the endothelial tube and aiding with capillary contraction. The degree of pericyte
coverage varies between organ types and exhibits a strong positive correlation with the
barrier function of the tissue, ranging from 1:1 (pericyte: endothelial cell) in the blood brain
barrier to as low as 1:10 in skeletal muscle (Diaz-Flores et al., 2009).
Pericytes are ubiquitously expressed in all microvessels, principally in the capillaries
but extending into both the precapillary arterioles and postcapillary venules (Nees et al.,
2013). The exact point at which pericyte coverage shifts to vSMC is controversial due to the
fact that definitive distinction between the two cell types is challenging. Others have
proposed that pericyte coverage extends into the largest coronary vessels, existing within
the extracellular matrix between the endothelial tube and internal elastic membrane as well
as supporting the vasa vasorum of the larger coronary arteries (Diaz-Flores et al., 2009).
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Figure 3.1.4.

Figure 3.1.4. Vascular pericyte coverage and pericyte anatomy.
(A) A single layer of vascular smooth muscle cells (vSMCs) surround the larger arterioles.
Beginning at the precapillary arteriole and then throughout the capillary, postcapillary venule
and venule, the vessel is supported by pericytes. As opposed to vSMCs, pericytes display a
prominent rounded cell body and long cytoplasmic processes. (B) Pericytes and endothelial
cells share a basement membrane and share many contacts [Source: Figure 1. Armulik, A.,
Genove, G., and Betsholtz, C. (2011). Pericytes: Developmental, Physiological, and
Pathological Perspectives, Problems, and Promises. Dev Cell 21, 193-215. (Armulik et al.,
2011). Used with permission from Elsevier, permission number 3581440915913].
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Pericyte recruitment and stabilization of the endothelium is dependent on multiple
signaling pathways, the complexity of which is demonstrated in Figure 3.1.5 and briefly
described in the following sections.
3.1.2.1 PDGF-B and PDGFRβ
The platelet-derived growth factor (PDGF) family consists of three dimers comprised
of two different disulfide linked polypeptide chains, PDGF-A and PDGF-B. The dimers most
often exist as homodimers, PDGF-AA or PDGF-BB, however it was the heterodimer, PDGFAB, that was first discovered in activated platelets (Andrae et al., 2008). Recently, two
additional PDGF factors, PDGF-C and PDGF-D have also been described (Bergsten et al.,
2001; Larochelle et al., 2001; Li et al., 2000). The PDGFs act in a paracrine manner, binding
to heparin and heparin sulfate proteoglycans in the extracellular matrix through an essential
C-terminal retention motif.
PDGFs act via two structurally related tyrosine kinase receptors, platelet-derived
growth factor receptor α and β (PDGFRα and PDGFRβ). PDGFRα can bind either PDGF-A
or PDGF-B. However, PDGFRβ appears to bind only PDGF-B (Leveen et al., 1994). Binding
induces receptor dimerization and activation of the downstream pathways Ras/MAPK,
PI3K/Akt and PKC. This results in actin reorganization, cell growth, migration and inhibition
of apoptosis (Andrae et al., 2008).
During angiogenesis, PDGF-BB is produced by the endothelial tip cells and binds to
PDGFRβ on the surface of developing pericytes (Gaengel et al., 2009). This process is
dependent on retention of PDGF-BB in the extracellular matrix as deletion of this motif in
mice (pdgfbret/ret) leads to pericyte detachment from the vessel wall and vascular
malformations in the kidney and retina (Lindblom et al., 2003). Similarly, knockout of the Ndeacetylase/N-sulfotransferase (NDST)-1 enzyme, leading to a reduction of N-sulfated
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heparin sulfate, also results in pericyte detachment (Abramsson et al., 2007). Deletion of
PDGF-B or PDGFRβ leads to almost identical perinatal lethality due to vascular
malformations resulting in widespread hemorrhage and edema (Armulik et al., 2011; Leveen
et al., 1994; Soriano, 1994). Loss of PDGF-B or PDGFRβ in an in vivo model of brain
angiogenesis resulted in endothelial cell hyperplasia, abnormal endothelial shape and
increased vascular permeability. Embryos from PDGF-B deficient mice also display
pronounced dilation of all chambers of the heart as well as significant enlargement of the
thoracic aorta (Leveen et al., 1994).
Only recently has the importance of PDGF-B/PDGFRβ signaling in maintaining
pericyte coverage in the adult been explored. These investigations have focused mainly on
tumor angiogenesis, diabetic retinopathy and neurobiology (Fernandez-Klett et al., 2010;
Gee et al., 2003; Song et al., 2005; Winkler et al., 2011). Furthermore, my previous lab has
reported that inducible cardiomyocyte-specific knockout of PDGFRβ in the adult mouse
results in ventricular dilation and heart failure in response to pressure overload stress
(Chintalgattu et al., 2010). This was correlated with impaired angiogenesis and
microvascular dysfunction in the adult heart.
3.1.2.2 Angiopoietin-1/Tie2
Angiopoeitin-1/Tie2 paracrine signaling exists in a reciprocal orientation to PDGFB/PDGFRβ. That is, pericytes produce angiopoietin-1 which binds to the endothelial Tei2
receptor, a receptor tyrosine kinase. Similar to PDGF-B/PDGFRβ, Angiopoeitin-1/Tie2
signaling promotes vessel maturation and stability (Falcon et al., 2009; Gaengel et al., 2009)
and reduced vessel leakiness (Thurston et al., 1999). Furthermore, angiopoeitin-1/Tie2
signaling is essential for normal cardiac development (Armulik et al., 2011). Genetic deletion
of either angiopoietin-1 or Tie2 leads death in utero due to cardiovascular abnormalities,
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Figure 3.1.5.

Figure 3.1.5. Signaling pathways mediating pericyte-endothelial cell interactions. The
close interaction between endothelial cells and pericytes is regulated by a large number of
pathways. However, the PDGF-B/PDGFRβ and Ang1/Tie2 interactions appear to be the
most important. [Source: Figure 4. Armulik, A., Genove, G., and Betsholtz, C. (2011).
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and
Promises. Dev Cell 21, 193-215. (Armulik et al., 2011) Used with permission from Elsevier,
permission number 3581440915913].
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characterized by detachment of the endocardium from the underlying myocardial wall and
absence of trabeculae (Jones et al., 2001; Patan, 1998). Similarly, missense mutations in
the human Tie2 receptor result in vascular malformations, resulting in multifocal bluish
lesions on the skin and mucosa (Limaye et al., 2009; Vikkula et al., 1996). Multiple cell types
produce

angiopoietin-1,

including

other

mesenchymal

cells,

cardiomyocytes,

and

hematopoietic cells; however the end result is much the same, promoting vascular stability
and higher-order structure and reducing leakiness, reviewed by (Jones et al., 2001).
3.1.2.3 Transforming growth factor beta
Both endothelial and mural cells produce transforming growth factor beta (TGFβ).
Signaling between the two is bidirectional and results in differentiation and maturation of the
vessel. TGFβ induces a mural cell fate in undifferentiated mesenchymal cells, a process that
is dependent on connexin-43 gap junction formation (Hirschi et al., 2003). TGFβ signals
through two receptors in vascular cells activin receptor-like kinase (Alk)-1 and Alk-5, which
have nearly opposing roles. Alk-5 activation inhibits migration and promotes mural cell
differentiation, whereas Alk-1 phosphorylation induces a more proliferative state, reviewed in
(Armulik et al., 2011). The two receptors are also regulated temporally, with Alk-1
dominating early development and Alk-5 inducing differentiation in later phases (Schmierer
and Hill, 2007). Deletion of downstream components of the TGFβ signaling pathway such as
smad4 (Lan et al., 2007), smad5 (Chang et al., 1999) and endoglin (Li et al., 1999) result in
embryonic lethality and vascular abnormalities.

3.1.3. Strategies to increase pericyte coverage and vessel normalization.
Tumor vasculature is structurally and functionally abnormal. Vessels are dilated,
tortuous, leaky and have absent or detached pericytes. This often results in interstitial
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hypertension, acidosis and hypoxia (Jain, 2005). Paradoxically, depletion of tumor pericytes
results in accelerated tumor growth and metastasis (Ramaswamy et al., 2003; Sennino et
al., 2007). Recent work has demonstrated that increasing pericyte coverage prevents tumor
growth. This process has been termed “vessel normalization”, because the vasculature
reverts to a near-normal phenotype.
3.1.3.1. Inhibition of VEGF-A
Treatment with bevacizumab, a monoclonal antibody directed against VEGF-A
results in a pruning of poorly formed vessels, specifically ones lacking pericyte coverage
(Winkler et al., 2004). Attempts to induce vessel normalization in cancer have focused
primarily on inhibition of VEGF-A signaling. Interestingly, cardiotoxicity is not associated with
agents that only inhibit VEGF-A signaling, such as bevacizumab (Khakoo et al., 2011).
Vessel normalization also occurs with deletion of the pericyte marker, regulator of G-protein
signaling 5 (RGS5), resulting in reduced leakiness and alleviation of hypoxia through an
unknown mechanism (Hamzah et al., 2008). The only other strategy that has proved
effective in normalizing tumor vasculature has been treatment with thalidomide.
3.1.3.2. Thalidomide
Thalidomide, a derivative of glutamic acid, was developed in the 1950s by the
German company, Chemie Grünenthal, and used primarily to combat morning sickness in
pregnant women. Though never approved by the FDA, thalidomide treatment led to severe
birth defects (malformed limbs) in between 8,000 and 12,000 children born in Europe,
Australia, Asia and South America (Bartlett et al., 2004). Thalidomide-induced teratogenicity
is due to a direct inhibition of cereblon (CRBN) (Ito et al., 2010). CRBN forms an E3 ligase
complex with damaged DNA binding protein 1 (DDB1) and Cul4A to target unidentified
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Figure 3.1.6.

Figure 3.1.5. CRBN is the primary target of thalidomide teratogenicity. Cereblon
(CRBN) forms an E3 ligase complex with damaged DNA binding protein 1 (DDB1) and
Cul4A to target unidentified substrates for degradation, leading to expression of fibroblast
growth factor 8 (FGF8) and normal limb outgrowth. Thalidomide directly binds to CRBN and
inhibits this process. [Source: Supplemental Figure 19 from Ito, T., Ando, H., Suzuki, T.,
Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa, H. (2010). Identification of a
Primary Target of Thalidomide Teratogenicity. Science 327, 1345-1350. (Ito et al., 2010)
Used with permission from the journal, license number: 3586070673111].
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substrates for degradation, leading to expression of fibroblast growth factor 8 (FGF8) and
normal limb outgrowth (Figure 3.1.6).
The catalyst for the current use of thalidomide occurred in 1964 when Israeli
physician Jacob Sheskin discovered that it could heal lesions in patients with erythema
nodosum leprosum, a complication of leprosy (Sheskin, 1964). Nearly 30 years later, it was
found that thalidomide had strong anti-inflammatory properties, primarily through inhibition of
monocyte-derived tumor necrosis factor alpha (TNFα) (Sampaio et al., 1991). Within that
same decade, thalidomide was found to be antiangiogenic (D'amato et al., 1994) and to costimulate T-cells previously activated by T-cell receptor (Haslett et al., 1998). The TNFαmediated anti-inflammatory properties of thalidomide has led to its use in several other
immune-system related complications such as Kaposi’s sarcoma (Little et al., 2000) and
cachexia (Gordon et al., 2005). Thalidomide has also significantly improved survival in
multiple myeloma, a B-cell derived malignancy that is associated with increased bonemarrow microvascular density. Furthermore, its co-treatment with dexamethasone led to full
remission in 10% of patients and partial remission in a quarter, leading to a clinical response
rate of 32% (Singhal et al., 1999).
Subsequently, two derivatives of thalidomide—lenalidomide and pomalidomide—
were developed which display 50,000 times more potency towards TNFα than thalidomide
(Bartlett et al., 2004). These derivatives do not appear to cause teratogenicity yet retain the
ability block angiogenesis. However as with thalidomide, the mechanism is still not well
understood (Lu et al., 2009). In a mouse model of hereditary hemorrhagic telangiectasia,
thalidomide increased pericyte coverage and induced vessel stabilization as well as
increased PDGF-B in endothelial cells (Lebrin et al., 2010). This chapter will demonstrate
that co-treatment with thalidomide can protect from sunitinib-induced pericyte loss and
preserve contractile function in mice.
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3.2 Results
3.2.1 Sunitinib induces cardiomyocyte hypertrophy.
Mice were treated with sunitinib for 21 days, a schedule that mimics the three weeks
on, one week off, clinical treatment schedule (see methods). Sunitinib treatment did not
result in increased heart weight to body weight ratios, which is normally indicative of cardiac
hypertrophy (Figure 3.2.1A). Nor was there evidence of pulmonary edema, as indicated by
normal lung weight to body weight ratios (Figure 3.2.1B). However, the increased
cardiomyocyte cross-sectional area (Figure 3.2.1C) suggests that there is cellular
hypertrophy despite no change in overall heart size.
Because sunitinib causes severe hypertension, mean-arterial pressure (MAP) was
measured over the course of treatment. Mice do not readily develop hypertension. Therefore
it was not much of a surprise that there was no increase in MAP (Figure 3.2.1D). This
indicated that sunitinib-induced cardiotoxicity may be the result of a direct cellular effect, and
not secondary to hemodynamic stress.

3.2.2 Sunitinib-induced cardiac contractile dysfunction is associated with
coronary microvascular dysfunction.
Measurement of left-ventricular ejection fraction by cardiac MRI revealed a
progressive decline over the course of 21 days (Figure 3.2.2A). This was associated with
decreased cardiac contractility in response to the inotropic agent dobutamine (Figure
3.2.2B), measured by the maximum developed pressure in the left ventricle over time
(dP/dtmax).
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Figure 3.2.1.

Figure 3.2.1. Sunitinib increases cardiomyocyte cross
cross-sectional
sectional area despite no
evidence of increased heart size. (A) Heart weight to body weight ratio. (B) Lung weight to
body weight ratio. (C) Lectin
Lectin-TRITC staining to demark cardiomyocyte
rdiomyocyte cell boarders and
cardiomyocyte cross-sectional
sectional area quantified to the right. (D) Mean arterial pressure over
the course of the 21 day treatment.
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Figure 3.2.2.

Figure 3.2.2. Sunitinib treatment leads to contractile and microvascular dysfunction.
(A) Cardiac ejection fraction as assessed by cardiac MRI. (B) Maximum developed pressure
over time (dP/dtmax) in the left ventricle in response to increasing concentration of
dobutamine. (C) Representative ultrasound tracings of stimulated and basal coronary flow in
the left-anterior
anterior descending coronary artery after 14 days of sunitinib treatment. Average
CFR (dilated:basal) over the 21 day treatment protocol. *P < 0.05.
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Coronary flow reserve (CFR), the change in blood flow velocity in the coronary artery
in response to a hyperemic stimulus, is clinically relevant measure that has been eloquently
adapted for the mouse heart (Hartley, Ultrasound in Medicine and Biology, 2008). Baseline
coronary flow is often elevated under load-induced cardiac hypertrophy in order to support
increased cardiac work (Hartley et al., 2011; Hartley et al., 2008). Consequentially, the
absolute rise to maximal coronary blood flow velocity, the coronary flow reserve, in blunted
in diseased states. Baseline coronary flow (1% isoflurane) was elevated in the sunitinibtreated and blunted upon stimulation (elevation of isoflurane levels to 2.5%), resulting in a
significantly decreased CFR in the sunitinib treated mice (Figure 3.2.2C). Collectively, these
results indicate that sunitinib-induced cardiotoxicity is associated with microvascular
dysfunction.

3.2.3. Sunitinib treatment results in reduced vascular reactivity.
Acetylcholine stimulation of the endothelium leads to activation of endothelial nitric
oxide synthase (eNOS) and consequent endothelium-dependent vascular relaxation and
increase in blood flow. Similar to isoflurane, acetylcholine infusion revealed that sunitinib
treatment leads to decreased CFR in vivo (Figure 3.2.3A). The same result was obtained
when acetylcholine-mediated increases in total coronary flow were measured using the ex
vivo Langendorff perfused heart preparation (Figure 3.2.3B). Ex vivo total coronary flow was
also decreased upon stimulation with the direct nitric oxide (NO) donor, sodium nitroprusside
(Figure 3.2.3C). As a direct donor of NO, sodium nitroprusside bypasses the endothelium to
directly induce vasorelaxation. Therefore, sodium nitroprusside is useful to determine if the
defect in vascular function resides in the ability of the mural cells to respond to NO. Given
the fact
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Figure 3.2.3.

Figure 3.2.3. Sunitinib is associated with decreased vascular reactivity. (A)
Acetylcholine-stimulated
stimulated coronary flow reserve in mice treated with sunitinib or vehicle for 14
days measured in vivo. (B) Acetylcholine-stimulated ex vivo total coronary flow in mice
treated with sunitinib for 14 days. (C) and (D) Total coronary flow in response to increasing
concentration of sodium nitroprusside or adenosine meas
measured in ex vivo Langendorff
perfused hearts from mice treated with sunitinib or vehicle.
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that ex vivo total coronary flow was also decreased in response to adenosine (endotheliumdependent) (Figure 3.2.3D), it appeared that sunitinib-induced microvascular dysfunction
might be due to vSMC or pericyte dysfunction.
In order to determine if sunitinib treatment also leads to macrovascular dysfunction,
vascular reactivity was assessed in isolated thoracic aortas with the help of Dr. Nathan
Bryan at The University of Texas’ Institute of Molecular Medicine. Isolated thoracic aortas
from mice treated with sunitinib or vehicle were exposed to phenylephrine or acetylcholine to
measure vascular constriction and relaxation, respectively (Figure 3.2.4A and Figure
3.2.4B). Sunitinib treatment had no effect on vasoconstriction or vasorelaxation of the large
vessels. However, there was a significant decrease in cardiac nitrite concentrations, a
byproduct of NO breakdown (Figure 3.2.4C). This indicated that sunitinib somehow alters
the ability of the cardiac vasculature to metabolize NO. Interestingly, there was no difference
in skeletal muscle nitrite levels, suggesting that sunitinib-induced vascular dysfunction may
be specific to the heart.

3.2.4. Sunitinib treatment leads to loss of microvascular pericytes and microvascular
abnormalities.
As described above, the largest resistance to flow in the heart is conferred by the
cardiac microvasculature. Supporting these small vessels are pericytes which, similar to
smooth muscle cells on larger vessels, provide structural and functional support. Scanning
electron microscopy revealed a loss of microvascular pericytes in sunitinib-treated hearts
(Figure 3.2.5A). This was confirmed by immunofluorescent microscopy of cardiac sections
stained for the proteoglycan neural/glial 2 (NG2), an established marker for pericytes
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Figure 3.2.4.

Figure 3.2.4. Sunitinib does not affect large
large-vessel reactivity. (A) and (B) Percent
contraction or relaxation of isolated thoracic aortas from mice treated with sunitinib or
vehicle stimulated with phenylephrine (PE) or acetylcholine (Ach). (C) and (D) Nitrite
concentration in cardiac and skeletal muscle tissue, respectively. *P < 0.05.
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(Ozerdem et al., 2001). Decreased NG2 expression was also observed by western blot
(Figure 3.2.5C).
Next, the functional consequence of pericyte loss in the heart was determined.
Pericyte loss has been linked to increased vascular permeability in both the blood-brain
barrier and tumors (Lindahl et al., 1997; Mccarty et al., 2007). Perfusion of isolated mouse
hearts with fluorescently labeled cadaverine, which in a healthy vasculature would remain
within the vessel, suggested that sunitinib treatment leads to increased vascular
permeability in the heart (Figure 3.2.6A). Absence of pericytes is also associated with
immature, poorly formed vessels which can be assessed by measuring vascular tortuosity
(Gaengel et al., 2009; Higuchi et al., 2000). Vascular tortuosity was significantly increased in
hearts from sunitinib-treated mice, as measured by a blinded third party (Dr. Jim Culver, as
a graduate student in the lab of Dr. Mary Dickinson at Baylor College of Medicine).
Together these data suggest that pericyte loss leads to a leaky, poorly formed vasculature.
They also indicate that the cardiac vasculature is dynamic, continuously remodeling in
response to stress.

3.2.5. Cardiac pericyte loss is also observed with the structurally distinct PDGFRβ
inhibitor, CP-673,451.
Noting that PDGFRβ signaling is essential for pericyte survival, it appeared that
sunitinib-induced pericyte loss might be due to inhibition of PDGFRβ. CP-673,451 is a
potent and specific PDGFRβ inhibitor that is structurally distinct from sunitinib (Figure
3.2.7A) (Roberts et al., 2005). Similar to sunitinib, treatment with CP-673,451 did not lead to
increased heart weight to body weight or lung weight to body weight ratios (Figure 3.2.7B).
However, a similar decline in left-ventricular ejection fraction was observed (Figure 4.2.7C)
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Figure 3.2.5.

Figure 3.2.5. Sunitinib treatment induces loss of microvascular pericytes. (A)
Representative scanning electron microscopy images of the cardiac microvasculature.
Vessels and pericytes are psuedocolored red and green respectively. (B) Confocal
Confo
images
from cardiac sections showing staining for the endothelial cell marker CD31 (red), pericyte
marker NG2 (green) or nuclear staining (DAPI, blue) and merged images (bottom left).
Pericyte coverage quantified to the right as the relative intensity of NG2:CD31. (C) NG2
protein expression in mice treated with sunitinib or vehicle. Right, densitometric
quantification.
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Figure 3.2.6.

Figure 3.2.6. Pericyte loss leads to microvascular abnormalities. (A) Representative
confocal images from mice treated w
with
ith sunitinib and perfused with 0.9 kDa cadaverine
conjugated to Alexa Fluor-555
555 demonstrating increased microvascular permeability. (B)
Computer-based
based reconstruction of the cardiac vasculature derived from the apex hearts
perfused with 70-kD
kD tetramethylrh
tetramethylrhodamine-labeled dextran and (below) quantification of
vascular tortuosity. ***P < .01.
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Figure 3.2.7.

Figure 3.2.7. Coronary microvascular dysfunction and pericyte loss are recapitulated
with the structurally distinct PDGFR
PDGFRβ inhibitor, CP-673451. (A) Chemical
emical structures of
sunitinib and CP-673451. (B) Heart weight to body weight and lung weight to body weight
ratios for mice treated with CP
CP-673451. (C) Cardiac ejection fraction at 7 and 14 days of
treatment as measured by cardiac MRI. (D) Coronary flow reserve
eserve at day 7 and 14 of CPCP
673451 treatment. (E) Representative confocal micrographs showing staining for the
vascular marker CD31 (red) or the pericyte marker NG2 (green) and merged images.
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and coronary flow reserve (Figure 3.2.7D). Most strikingly, CP-673,451 treatment resulted
in a similar loss of cardiac microvascular pericytes (Figure 3.2.7E). These data suggest that
loss of PDGFRβ signaling underlies the development of contractile and microvascular
toxicity due to sunitinib.

3.2.6. Pericyte loss is not a general feature of cardiotoxicity.
As described in Chapter 1, doxorubicin is a general DNA intercalating agent that
causes cardiac injury through the generation of reactive oxygen species. Both low dose
(5mg/kg/wk.) and high dose (10mg/kg/wk.) doxorubicin treatment led to decline in leftventricular ejection fraction (Figure 3.2.8A) and coronary flow reserve (Figure 3.2.8B).
However, there was no observable loss of the pericyte marker NG2 by either western blot
(Figure 3.2.8C) or immunofluorescence (Figure 3.2.8D). Therefore pericyte loss appears to
be a specific feature of sunitinib cardiotoxicity and not a general feature of cardiac injury by
chemotherapeutic agents.
3.2.7. Co-treatment with thalidomide ameliorates sunitinib-induced contractile
dysfunction and pericyte loss.
To test whether sunitinib was directly toxic to pericytes in vitro, the viability of human
placental pericytes treated with sunitinib was determined using an MTT colorimetric assay
(see methods). Cell viability was inversely correlated with the concentration of sunitinib
(Figure 3.2.9A). As described above, thalidomide is known to increase vascular pericyte
coverage. Co-treatment of isolated pericytes with sunitinib and thalidomide significantly
increased cell viability, though not to control levels (Figure 3.2.9B). Neither sunitinib alone
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Figure 3.2.8.

Figure 3.2.8. Doxorubicin treatment does not cause pericyte loss. (A) Cardiac ejection
fraction in mice treated with doxorubicin or vehicle, measured by cardiac MRI. (B) Coronary
flow reserve at day 1, 7 and 14 of treatment. (C) NG2 protein expression from cardiac
lysates of mice treated with doxorubicin or vehicle. (D) Confocal micrographs stained for the
endothelial marker CD31 (red), pericyte marker NG2 (green), nuclei (DAPI, blue) and
merged images.
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Figure 3.2.9

induced pericyte death is rescued by thalidomide in vitro. (A)
Figure 3.2.9. Sunitinib-induced
Pericyte viability measured by <
<TT
TT assay after 24 hour treatment with increasing
concentrations of sunitinib. (B) Pericyte viability after 24 hour treatment with sunitinib alone
or plus thalidomide. (C) Neither sunitinib alone nor co
co-treatment
treatment with thalidomide affects
fibroblast or endothelial
helial cell viability.
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nor co-treatment with thalidomide had any effect on fibroblast or endothelial cell viability
(Figure 3.2.9C). This suggests that sunitinib-induced cardiotoxicity may be directly related to
its effects on pericytes and that pericytes are specifically protected by thalidomide.
Therefore, if thalidomide could restore pericyte coverage in the heart, sunitinib
induced cardiotoxicity might be prevented. Mice were treated with sunitinib alone or sunitinib
plus thalidomide for 14 days followed by 14 days of recovery. Thalidomide protected from
both sunitinib-induced reductions in both contractile (Figure 3.2.10A) and microvascular
(Figure 3.2.10B) dysfunction during the treatment phase and this protection extended into
the recovery period. Lastly, confocal microscopy revealed that thalidomide co-treatment
preserved pericyte coverage of coronary microvessels (Figure 3.2.10C). These findings
demonstrate that sunitinib-induced pericyte depletion may be directly responsible for
sunitinib-induced cardiac dysfunction.

3.2.8. Thalidomide does not alter the anti-tumor efficacy of sunitinib.
To

determine

whether

thalidomide

may

represent

a

novel

strategy

for

cardioprotection during sunitinib treatment, the ability of sunitinib to halt tumor growth was
evaluated in the presence of thalidomide. As a single treatment, thalidomide only mildly
slowed tumor growth compared to sunitinib in a human renal cell carcinoma xenograft model
(Figure 3.2.11A). However more importantly, the rate of tumor growth with co-administration
of thalidomide and sunitinib was no different than sunitinib alone. As observed in non-tumor
bearing mice, co-treatment with thalidomide protected from sunitinib-induced contractile
dysfunction (Figure 3.2.11B) and decrease in coronary flow reserve (Figure 3.2.11C).
Collectively, this data demonstrates that co-treatment with thalidomide may be a viable
strategy for cardioprotection in patients receiving sunitinib.
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Figure 3.2.10.

Figure

3.2.10.

Co-treatment
treatment

with

thalidomide

prevents

sunitinib
sunitinib-induced

cardiovascular dysfunction and pericyte loss. (A) Left-ventricular
ventricular ejection fraction in
mice treated with sunitinib alone (control) or sunitinib plus thalidomide (thalidomide) for 14
days followed byy a 14 day recovery period. (B) Coronary flow reserve in mice treated with
sunitinib alone or sunitinib plus thalidomide. Data is shown as the flow reserve index, or the
ratio of mice treated with sunitinib alone to mice treated with sunitinib plus vehicle.
vehicle (C)
Confocal micrographs stained for the endothelial marker CD31 (red), pericyte marker NG2
(green), nuclei (DAPI, blue) and merged images. *P < 0.05.
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Figure 3.2.11.

Figure 3.2.11. Co-treatment
treatment with thalidomide does not alter the anti
anti-tumor
tumor capability
capabili
of sunitinib. (A) Average tumor volume over time in untreated mice or mice treated with
sunitinib alone, thalidomide alone or sunitinib plus thalidomide. (B) and (C) Left-ventricular
ejection fraction and coronary flow reserve in tumor
tumor-bearing mice at day
ay 0, 14 and 28 of
treatment. *P < 0.05.
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4. Discussion
The data presented here indicate that the primary cellular target of sunitinib is the
pericytes surrounding the coronary microvasculature. Furthermore, pericyte loss leads to
vascular abnormalities and cardiac dysfunction in the adult heart. It is known that pericyte
loss leads to abnormal cardiac development and death during development (Bjarnegard et
al., 2004; Jeansson et al., 2011). The data I presented here suggest that pericyte survival is
similarly essential in the adult heart.
Sunitinib-induced cardiac dysfunction is mostly reversible with drug withdrawal
(Uraizee et al., 2011); both cardiac and microvascular dysfunction slowly return to normal,
suggesting that pericyte coverage also increases (Figure 3.2.10). It remains to be
determined whether sunitinib treatment induces pericyte apoptosis in vivo, similar to pericyte
loss in diabetic retinopathy (Geraldes et al., 2009). Or, whether the pericytes dedifferentiate
and migrate away from the endothelium as occurs during cerebral ischemia (Thomas, 1999).
My in vitro experiments (Figure 3.2.9) reveal a direct toxic effect of sunitinib on pericytes,
suggesting that sunitinib treatment leads to pericyte cell death in the heart. Thus, the
restoration of pericyte coverage may be the result of the transdifferentiation of
myofibroblasts, smooth muscle cells or even endothelial cells in the heart (Deruiter et al.,
1997; Nehls and Drenckhahn, 1993). Future studies may take advantage of cellular fate
mapping tools, such as endothelial cell-specific expression of a myristoylated mCherry
fluorescent protein (Poche et al., 2009), to determine the source of pericytes in the
recovering sunitinib-treated heart.
The mechanism by which thalidomide protects from sunitinib-induced pericyte death
remains unknown. Loss of microvascular pericytes in rat models of both Type I
(streptozotocin-induced) or Type II (Zucker Diabetic Fatty rat) diabetes is associated with
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high levels of TNFα (Behl et al., 2008). TNFα was also associated with pericyte
dedifferentiation

and

proliferation

in

an

experimental

model

of

autoimmune

encephalomyelitis (Tigges et al., 2013). Furthermore, pharmacological blockade of TNFα is
sufficient to prevent pericyte cell death both in vitro and in vivo (Behl et al., 2008; Joussen et
al., 2009; Tigges et al., 2013). Blockade of TNFα is the primary mechanism by which
thalidomide improves autoimmune diseases and slows growth in multiple myeloma.
Therefore it’s possible that protection of coronary microvascular pericyte from sunitinibinduced cell death may be due to inhibition of TNFα. It would be interesting to determine if
specific inhibition of TNFα could protect from sunitinib-induced cardiotoxicity. Although the
combination of sunitinib and thalidomide did not slow tumor growth beyond sunitinib
treatment alone (Figure 3.2.11), it is possible that more potent inhibition of TNFα—such as
with lenalidomide or pomalidomide—in combination with sunitinib would be beneficial. In
fact, several clinical trials evaluating lenalidomide as a single treatment for metastatic renal
cell carcinoma have demonstrated positive results (Amato et al., 2008; Choueiri et al., 2006;
Pal et al., 2012). Additional clinical studies will be necessary to determine whether sunitinibinduced coronary microvascular dysfunction and pericyte loss also occur in humans, and
whether thalidomide represents a rational cardioprotection strategy for patients at high risk
for cardiotoxicity due to sunitinib.
Pericyte loss is not a general feature of cardiac injury (Figure 3.2.8). Nonetheless,
pericyte loss occurs during cerebral ischemia and in the early phases of diabetic retinopathy
(Geraldes et al., 2009; Thomas, 1999). Therefore, it would be interesting to determine
whether pericyte loss occurs in other forms of heart failure such as ischemic cardiomyopathy
or diabetic cardiomyopathy. Along that same line, the exact mechanism by which pericyte
loss leads to cardiac dysfunction remains to be fully explored. To this end, my previous lab
performed gene expression microarrays on mice treated with sunitinib or vehicle for 3 or 7
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days (Figure 3.2.12). Of 51 genes upregulated by at least 15%, 14 genes are known to be
regulated by hypoxia inducible factor 1 alpha (Hif1α). Of these 14 genes, PHD3, BNIP3, cmyc, Angptl4, and EDN1 are specifically upregulated in the hypoxic heart. It is possible that
sunitinib-induced microvascular dysfunction leads to myocardial hypoxia, inducing a state
similar to the hibernating myocardium (Ammirati et al., 2011; Kloner et al., 1989).
Hibernating myocardium is defined as dysfunctional but still viable tissue and is discussed
most often in the setting of left ventricular systolic dysfunction due to coronary artery
disease. My data presented in the next chapter will suggest a possible connection between
pericyte loss, hypoxia and dysfunction.
Lastly, pericyte loss may not be the only mechanism by which sunitinib could cause
cardiac dysfunction. As discussed in Chapter 1, sunitinib has also been shown to directly
inhibit adenosine monophosphate activated kinase (AMPK) (Kerkela et al., 2009; Laderoute
et al., 2010). Sunitinib-induced changes in cardiac metabolism, specifically increased
glucose metabolism, are the subject of the next chapter.
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Figure 3.2.12.

Figure 3.2.12. Microarray analysis of hearts from mice treated with sunitinib or vehicle
for 3 or 7 days. (A) Fold change in expression of selected genes associated with hypoxia
identified by the Affymetrix microarray. (B) qPCR confirmation of increased PHD3
expression in the hearts of mice treated with sunitinib for 3 or 7 days. *P<0.05.
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Chapter 4
Altered Glucose Metabolism and a PKM2 Signature in the
Failing Heart

Note: Several figures presented here are published in (Rees et al., 2015) Used with
permission from Elsevier, license number: 500977596.
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4.1 Introduction

4.1.1 Sunitinib lowers blood glucose levels in patients.
In addition to inducing cardiovascular dysfunction in a subset of patients, sunitinib
dramatically lowers blood glucose levels in both diabetic and non-diabetic patients.
Beginning as far back as 2004, a sprinkling of case reports have described a normalization
of blood glucose levels in diabetic patients receiving sunitinib or the related receptor tyrosine
kinase inhibitors imatinib, sorafenib and dasatinib (Billemont et al., 2008; Breccia et al.,
2005; Breccia et al., 2004; Louvet et al., 2008; Mokhtari and Welsh, 2010; Templeton et al.,
2008; Tsapas et al., 2008; Veneri et al., 2005). Agostino et al performed a retrospective
study of blood glucose levels in both diabetic (17) and non-diabetic (61) patients treated
with: imatinib (39), sunitinib (30), sorafenib (23) or dasatinib (8) (Agostino et al., 2011). The
authors found significant decreases in blood glucose levels ranging from 53 mg/dL with
dasatinib to 9 mg/dL with imatinib. Importantly, 47% (8/17) of the diabetic patients
discontinued their medications, including some patients on insulin treatment.
Common to all these RTKIs is inhibition of PDGFRβ, Accordingly, the proposed
mechanism for this phenomenon has thought to be the preservation of pancreatic beta cells
through inhibition of PDGFRβ. In the most prominent paper promoting this hypothesis, the
authors found that only drugs whose targets include the PDGFRβ (imatinib, sunitinib and a
PDGFRβ-Ig) could both reverse and prevent the development of diabetes in the NOD
mouse model of type I diabetes (Louvet et al., 2008). This was compared to specific
inhibition of c-kit with PLX647, a monoclonal antibody that has also been proposed to
mediate glycemic control (Mokhtari and Welsh, 2010). Several other investigators
demonstrated preservation of pancreatic beta cells both in streptozotocin-treated rats and in
the db/db mouse (Hagerkvist et al., 2008; Han et al., 2009). However this class of drugs,
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specifically ones that target PDGFRβ, lower blood glucose levels in patients with type 2
diabetes as well, suggesting an alternative mechanism of glycemic control besides
preservation of pancreatic beta cells, namely increased insulin action in the peripheral
tissues. This concept is supported by the observation that imatinib increased insulin
sensitivity and glucose disposal rates in rats fed a high fat diet (Hagerkvist et al., 2008).
Based on electron microscopy images demonstrating apparent mitochondrial
structural abnormalities in the heart, Force et al proposed that cardiotoxicity due to imatinib
and sunitinib may be due to mitochondrial defects (Force et al., 2007). Following this
observation, a group at the pharmaceutical company Pfizer measured mitochondrial function
in isolated rat mitochondria and H9C2 cells treated with imatinib, sunitinib, sorafenib and
dasatinib (Will et al., 2008). Of the four kinase inhibitors tested, only sorafenib significantly
affected isolated mitochondrial function and resulted in decreased ATP content in H9C2
cells. This indicated that mitochondrial dysfunction is most likely not the cause of sunitinib
cardiotoxicity and confirmed the sentiment that the membrane whorls observed on
transmission electron micrographs were most likely a freezing artifact (Dr. Michael Ewer, MD
Anderson Cancer Center, personal communication).

4.1.2 Increased glucose metabolism and induction of the fetal gene program in
the failing heart.
Mounting evidence from our lab and others indicates that glucose uptake in excess
of the heart’s capacity to oxidize glucose contributes to cardiovascular dysfunction. For
instance, the ACCORD trial found that intensive glucose lowering therapies (targeted
HbA1C levels below 6%) actually increase the incidence of death from cardiovascular
disease in patients with type 2 diabetes. Given this high association between intensive
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glucose lowering and cardiovascular dysfunction, I asked whether sunitinib similarly drives
glucose uptake in excess of the heart’s oxidative capacity.
A hallmark of the fetal heart is the use of carbohydrate substrates as the primary
source of energy (Rajabi et al., 2007). The greater efficiency of carbohydrate substrates per
mole of oxygen allows the fetal heart to withstand its low oxygen environment, rapidly
changing hemodynamic load and demand for growth (Rajabi et al., 2007). Shortly after birth,
as the maternal supply of nutrients is lost, the heart is exposed to a period of starvation
where it rapidly depletes its glycogen stores and promptly switches to the oxidation of fatty
acids. This process appears to require the induction of autophagy as deletion of the
autophagasome elongation factor, ATG5, results in rapid post-natal lethality (Kuma et al.,
2004). Though displaying a preference for fatty acids, the adult heart is an omnivore,
capable of utilizing a wide range of additional carbon sources, such as lactate and ketone
bodies, in response to metabolic milieu and hemodynamic load (Taegtmeyer, 1994).
The failing heart returns to predominant glucose utilization for energy provision. This
is achieved, in part, through induction of the fetal gene program. The primary argument for
this effect relates to the higher efficiency of glucose oxidation compared to the oxidation of
fatty acids. The most convincing evidence for this comes from a study in the isolated
working rat heart subjected to an abrupt increase in cardiac work (Goodwin et al., 1998) and
a study by Korvald et al (Korvald et al., 2000). In this study, myocardial oxygen consumption
and cardiac performance were measured in vivo using anesthetized pigs. For the same
amount of cardiac work, oxygen consumption was 48% higher when pigs were infused with
intralipid-heparin (IH) compared to infusion of glucose, insulin and potassium (GIK).
Alternatively stated, for the same amount of oxygen consumed, glucose supports
significantly more cardiac work. For this reason, activation of the fetal gene program is
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thought to be mostly adaptive, provided glucose uptake and oxidation are matched (Rajabi
et al., 2007).
Prominent features of the fetal gene program include myosin heavy chain (MHC)
isoform switching from MHCα to MHCβ, expression of atrial naturietic factor (ANF) and
activation of the transcription factors c-myc and c-fos (Rajabi et al., 2007). The switch to
glucose oxidation results from primarily from the downregulation of adult genes such as
GLUT4, pyruvate dehydrogenase kinase 2 (PDK2), muscle carnitine palmitoyl transferase 1
(mCPT-1) and medium-chain acyl-CoA decarboxylase (MCAD), (Barger and Kelly, 1999;
Razeghi et al., 2001). In the course of work on my dissertation I have shown that induction
of another fetal gene, the M2 isoform of pyruvate kinase (PKM2), may provide a link
between activation of the fetal gene program and upregulation of glycolysis.

4.2 Results
4.2.1. Sunitinib treatment results in increased insulin sensitivity.
In order to test whether sunitinib affects blood glucose levels regardless of diabetic
status, I tested insulin sensitivity in non-diabetic C57BL/6J mice. Sunitinib treated mice had
decreased serum glucose levels (Figure 4.2.1A) despite significantly decreased circulating
insulin levels (Figure 4.2.1B). This suggested to me that sunitinib increases insulin
sensitivity as both groups consumed the approximately same number of calories per mouse
per day (Figure 4.2.1C). Significantly increased insulin sensitivity was confirmed by an
insulin tolerance test (Figure 4.2.1D) as well as by the slightly enhanced glucose clearance
observed in an oral glucose tolerance test (Figure 4.2.1E).
Based on these findings, hyperinsulinemic euglycemic clamp studies were performed
in the Mouse Metabolism Core at Baylor College of Medicine. The hyperinsulinemic
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euglycemic clamp is considered the gold standard by which to characterize insulin sensitivity
(Defronzo et al., 1979). Measurement of tissue-specific glucose uptake can be achieved
using [U-14C]-2-deoxyglucose (2DG), or the related tracer, 2-deoxy-2-[18F]fluoro-D-glucose
(FDG) (Figure 4.2.2A).
2DG and FDG are readily taken up by the cell and phosphorylated but not further
metabolized, permitting an estimation of tissue glucose uptake (Nguyen et al., 1990). It is
important to note, however, that glucose uptake is underestimated when 2DG is used,
making assessment of myocardial glucose uptake with 2DG is qualitative rather than
quantitative. Under non-steady state conditions, (i.e. the presence of insulin, competing
substrates or ischemia) there is a discordant affinity of hexokinase for glucose versus FDG,
with a stronger preference for glucose (Doenst and Taegtmeyer, 1998; Hariharan et al.,
1995). Non-steady state conditions lead to a change in the lumped constant (LC), which is,
in fact, not a constant but rather a conversion factor used to convert the rates of tracer
uptake to the rates of tracee uptake. However, the LC can be predicted using a time-activity
curve generated from the measured rates of [2-3H]glucose and FDG glucose uptake under
the same conditions (Bøtker et al., 1999).
The steady-state glucose infusion rate was significantly increased in the sunitinib
group (Figure 4.2.2B). Once steady-state conditions are reached, the rate of glucose
infusion is equal to the rate of glucose disposal and the rate of peripheral glucose uptake
can be approximated. The glucose disposal rate was significantly increased in the sunitinib
group (Figure 4.2.2C) and [U-14C]-2DG uptake revealed a fivefold and sevenfold increase in
the heart and skeletal muscle, respectively (Figure 4.2.2D).
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Figure 4.2.1.

Figure 4.2.1. Sunitinib increases systemic insulin sensitivity. (A) Non-fasted
Non
serum
glucose levels. (B) Non-fasted
fasted serum insulin. (C) Average caloric intake per day over the
course of treatment. (D) Insulin tolerance test. (E) Oral glucose tolerance test. *P < 0.05 and
**P < 0.01.
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Figure 4.2.2.

Figure 4.2.2. Hyperinsulinemic euglycemic clamp procedure in mice treated with
sunitinib. (A) Summary of the clamp procedure. (B) Steady-state
state glucose infusion rate. (C)
Glucose disposal rate calculated from the steady
steady-state glucose disposal
isposal rate. (D) [U-14C]-2deoxyglucose uptake in the heart and skeletal muscle. *P < 0.05, **P < 0.01 and ***P <
0.001.
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A hallmark of the fetal heart is the reliance on glucose metabolism as the primary
source of energy provision. The greater efficiency of glucose oxidation permits the fetal
heart to adapt to its low oxygen environment and demand for growth. With exposure to the
oxygen-rich post-natal environment and the rapid depletion of endogenous substrate stores,
the heart rapidly switches to fatty acid oxidation. However, a salient feature of the failing
heart is metabolic remodeling from predominant fatty acid oxidation to carbohydrate
metabolism.
Transcript analysis by qPCR revealed a significant upregulation of glycolytic genes,
specifically pointing to the redirection of glucose towards lactate production (Figure 4.2.3A).
This corresponded to reduced enzyme activity of pyruvate kinase (Figure 4.2.3B) and
increased lactate dehydrogenase activity (Figure 4.2.3C). Hallmarks of the fetal gene
program, which include a switch in the contractile protein isoforms from myosin heavy chain
α (MHCα) to MHCβ and increased expression of atrial naturetic factor (ANF), c-myc and cfos (Rajabi et al., 2007), were increased in the sunitinib-treated hearts (Figure 4.2.3D).
Thus, sunitinib treatment leads to upregulation of the fetal gene program in the heart.
Upregulation of the fetal gene program and increased glycolysis are intimately linked with
cardiac hypertrophy. Correspondingly, I observed an increase in cardiomyocyte crosssectional area in sunitinib-treated mice (Figure 4.2.3E). Interestingly, I did not observe an
increase in the heart weight to body weight ratio, which suggests that cardiac hypertrophy
and apoptosis occurs side-by-side and may be a unique feature of sunitinib cardiotoxicity
(Figure 4.2.3F).
4.2.3. Glucose is redirected into secondary pathways of metabolism.
Glycogen occupies about 2% of the cell volume in the adult cardiomyocyte, however
comprises nearly a third of the cell volume in the fetal heart (Rajabi et al., 2007).
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Figure 4.2.3.

Figure 4.2.3. Sunitinib treatment increase
increases glycolysis in the heart.
rt. (A) Transcript
analysis by qPCR of key glycolytic genes. (B) Enzyme activity of pyruvate kinase. (C)
Lactate dehydrogenase enzyme activity. (D) qPCR analysis demonstrating activation of the
fetal gene program (E) Hemotoxylin and Eosin (H&
(H&E)
E) staining of cross sections from mice
treated with sunitinib or vehicle. Cardiomyocyte cross
cross-sectional
sectional area is quantified to the
right. (F) Ratio of heart weight to body weight. *P < 0.05.
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Correspondingly, I observed significant glycogen accumulation in sunitinib treated hearts
(Figure 4.2.4A). This was suggestive of an overflow of glucose into secondary pathways of
glucose metabolism. Accordingly, I observed a significant increase in O-Linked β-Nacetylglucosamine (O-GlcNAc) modification of cardiac proteins (Figure 4.2.4B). O-GlcNAc
is a product of the hexosamine biosynthetic pathway and results from conversion of glucose
6-phosphate to fructose 6-phosphate, glucosamine-6-phosphate and ultimately to UDPGlcNAc (Ngoh et al., 2010; Watson et al., 2010). Similar to phosphorylation, it is rapidly
cycled on and off proteins via the action of O-GlcNAc transferase and O-GlcNAcase.
Sunitinib-induced cardiotoxicity is a unique model of cardiac dysfunction and it is unclear
what the role of O-GlcNAcylation is in the sunitinib-treated heart.
It is of note that in the hearts from sunitinib-treated animals, the levels of glucose-6phosphate are significantly decreased (Figure 4.2.4C). I have verified these measurements
by repeated assays. The results suggest that G6P is metabolized by at least three different
pathways: glycolysis, glycogen synthesis and the hexosamine biosynthetic pathway. Future
work may determine the flux rates through the individual pathways.
4.2.4. Sunitinib treatment leads to induction of PKM2.
Increased glycolysis, slowed pyruvate kinase activity and redirection of glucose into
secondary pathways of metabolism were reminiscent of the Warburg Effect in cancer. Since
its first description by Otto Warburg, reviewed by (Warburg, 1956), the Warburg Effect has
evolved to describe the upregulation of glycolysis by cancer cells and the redirection of
glucose-derived carbons into biosynthetic pathways (Vander Heiden et al., 2009). One of
the drivers of the Warburg Effect in cancer is the induction of the fetal, M2 isoform of
pyruvate kinase (PKM2). Because I had observed activation of the fetal gene program in the
sunitinib
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Figure 4.2.4.

Figure 4.2.4. Glucose is redirected into secondary pathways of glucose metabolism.
metabolism
(A) Cardiac glycogen content as assessed by Periodic Acid
Acid-Schiff
Schiff staining and quantified to
right by tissue extraction and enzyme
enzyme-coupled spectroscopy.

(B) Western blot

demonstrating
ing increased O
O-GlcNAcylation of cardiac proteins. (C) Cardiac glucose 66
phosphate levels. *P < 0.05 and ***P < 0.001.
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treated heart, I asked whether PKM2 induction also occurs with sunitinib treatment.
Digestion of the PKM cDNA product with the restriction enzyme Pst1 (Figure 4.2.5A)
revealed a significant increase in the percentage of PKM2 in the heart (Figure 4.2.5B). This
was confirmed by both western blot (Figure 4.2.5C) and qPCR (Figure 4.2.5D). Thus, in
hearts from sunitinib treated mice, PKM2 is upregulated like in cancer cells.

4.2.5. Sunitinib treatment leads to activation of Hif1α and c-myc.
Under normoxic conditions, the master hypoxia response factor, hypoxia inducible
factor 1α (Hif1α) is hydroxylated by a family of prolyl-hydroxylases and subsequently
targeted for ubiquitin-mediated proteasomal degradation by the von Hippel–Lindau protein
(VHL). When the oxygen level in the cell falls, Hif1α translocates into the nucleus where it
heterodimerizes with Hif1β and activates a host of genes, including PKM2. Hydroxylated
PKM2, in turn, upregulates Hif1α expression in a positive feed-forward loop.
Sunitinib treatment resulted in increased Hif1α protein expression in the nuclear
fraction of hearts from mice treated with sunitinib (Figure 4.2.6A) as well as an upregulation
of Hif1α transcript levels (Figure 4.2.6B) and transcript levels of Hif1α-induced genes
(Figure 4.2.6C). This suggests that activation of Hif1α may be an important contributor to
the induction of PKM2 in the heart.
Alternative splicing of the PKM gene is dependent on three heterogeneous nuclear
ribonucleoprotein (hnRNP) proteins: polypyrimidine tract binding protein (PTB, also known
as hnRNPI), hnRNPA1 and hnRNPA2. At high levels, these factors bind to the intronic
sequence flanking exon 9 and inhibit the inclusion of exon 9 (PKM1) in the mRNA product
(Luo and Semenza, 2012). Upregulation of these factors is promoted by the oncogenic
transcription factor c-myc (David et al., 2010). In the heart, c-myc is induced by pressure
105

Figure 4.2.5.

Figure 4.2.5. Sunitinib treatment results in induction of the M2 isoform of pyruvate
kinase. (A) Diagram detailing the alternative splicing of the PKM gene and resulting cDNA
products and restriction enzyme sites. (B) Pst1 digest of the PKM cDNA products and
resulting percentage of PKM2, quantified to the right. (C) Western blotting of PKM2 and
PKM1 mice treated with sunitinib (S) or vehicle (V). (D) qPCR quantification of PKM1 and
PKM2 transcript levels. *P < 0.05.
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Figure 4.2.6.

Figure 4.2.6. Sunitinib treatments results in the activation of Hif1
Hif1α and c-myc.
c
(A)
Western blotting for Hif1α
α in the nuclear fraction of cardiac tissue lysates. (B) qPCR
measurement of Hif1α and (C) Hif1α-target genes expression in the heart. (D) Western blot
of c-myc
myc protein expression in the nuclear fraction of cardiac tissue lysates. (E) Transcript
analysis of c-myc and (F) of key PKM2 splicing factors induced by cc-myc.
myc. *P < 0.05.
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overload (Mulvagh et al., 1988). Additionally, coronary flow is a strong determinant of c-myc
expression (Bauters et al., 1988). Nuclear c-myc protein (Figure 4.2.6D) and mRNA (Figure
4.2.6E) expression levels were significantly increased in sunitinib-treated hearts. Transcript
levels of PTB, hnRNPA1 and hnRNPA2 were similarly increased in sunitinib treated hearts
(Figure 4.2.6F). These findings further support the critical role of PKM2 expression (and the
Warburg Effect) in hearts from sunitinib treated animals.

4.2.6. Hif1α activation results in PKM2 induction in the heart.
In order to determine directly whether hypoxia was sufficient to induce PKM2
expression in the heart, mice were housed in an 8% oxygen environment for 24 hours. As a
result, PKM2 expression was increased in the heart, but not in skeletal muscle (Figure
4.2.7A). I next determined whether PKM2 induction could be induced in vitro. Not
unexpectedly, the immortalized cardiac cell line H9C2 and neonatal rat ventricular myocytes
(NRVMs) only express PKM2 whereas isolated adult mouse cardiomyocytes express
primarily PKM1 (Figure 4.2.7B). Thus the isolated adult cardiomyocytes proved ideal to
study the induction of PKM2 in the heart. Twenty-four hour exposure of isolated adult
cardiomyocytes

to

1%

oxygen

or

to

the

pharmacological

hypoxia

mimetics,

dimethyloxalylglycine (DMOG) and cobalt chloride, resulted in increased PKM2 expression
compared to sunitinib treatment or untreated controls (Figure 4.2.7C). These results are
important because they indicate that the pyruvate kinase isoform switch is mediated by
oxygen deprivation and not as a direct effect of sunitinib.

4.2.7. PKM2 is induced in the failing human heart.
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Figure 4.2.7.

Figure 4.2.7. Hif1α activation results in PKM2 induction in the heart. (A) Percent PKM2
expression in mice subjected to normoxia (21% oxygen) or 8% oxygen for 24 hours. (B)
Percent PKM2 expression in the H9C2 cell line, neonatal rat ventricular myocytes (NRVMs)
(N
or isolated adult cardiomyocytes. (C) Percent PKM2 expression in isolated adult
cardiomyocytes exposed to 1% oxygen or treated with the pharmacological mimetics
dimethyloxalylglycine (DMOG) or cobalt chloride (CoCl2) for 24 hours. * P < 0.05.

109

To determine the clinical relevance of my findings I evaluated PKM2 expression in
heart muscle samples from non-failing and failing human hearts, the latter before and after
mechanical unloading with a left-ventricular assist device (LVAD). Compared to non-failing
hearts, PKM2 expression, assessed by qPCR, was significantly increased in the failing heart
muscle samples (Figure 4.2.8A). This observation was confirmed by western blot (Figure
4.2.8B). It appeared that the induction of PKM2 regressed with mechanical unloading. I
therefore evaluated PKM2 expression in a total of 13 paired samples and found a significant
decrease in PKM2 expression in the explant heart muscle samples (Figure 4.2.8C). Similar
to the mouse samples, PKM2 induction was correlated with O-GlcNAcylation of proteins in
the human hearts (Figure 4.2.8D). The results confirm the lab’s earlier observations that the
failing human heart reverts to the fetal genotype (Razeghi et al., 2001). They also show, for
the first time, a partial reversal with mechanical unloading.

4.3 Discussion
It has long been assumed that PKM2 is an oncogene, specifically selected by the
tumor to drive growth. Yet the question remains why there is selection for PKM2 rather than
a silencing or mutation of PKM1. A recent report from the Vander Heiden lab demonstrated
that—surprisingly—deletion of PKM2 results in more aggressive tumors (Israelsen et al.,
2013). It seems that selection for PKM2 permits metabolic flexibility, allowing for either
pyruvate generation or a redirection of glucose-derived carbons into biosynthetic pathways
for growth. In the postmitotic cardiomyocyte, the role of PKM2 induction in the failing heart
may have a similar role.
Glucose metabolism in the hemodynamically stressed heart is finely regulated and
can be both adaptive and maladaptive. For instance, overexpression of the glucose
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Figure 4.2.8.

Figure 4.2.8. Induction of PKM2 in the failing human heart
heart. (A) Percent PKM2
expression in non-failing,
failing, or failing human hearts before and after LVAD implantation. (B)
Protein expression of PKM2 and PKM1 in heart muscle samples. (C) Percent PKM2
expression in paired heart muscle samples from before and after LVAD implantation.
impl
(D)
Quantification of O-GlcNAcylated
GlcNAcylated proteins in non
non-failing
failing and paired failing human heart
muscle samples at the time of LVAD implant (I) and explant (E) by Western Blot. *P < 0.05
and **P < 0.01.
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transporter, GLUT1, prevents the development of heart failure in response to pressure
overload stress as well as protects from ischemic injury in both young and aged mice (Liao
et al., 2002; Luptak et al., 2007). Knockdown of acetyl-CoA carboxylase 2 (ACC2) enhances
rates of fatty acid oxidation, prevents hypertrophy and preserves cardiac function (Essop et
al., 2008; Kolwicz et al., 2012). Similarly, high fat feeding prevents hypertrophy-induced
cardiac remodeling in rats (Okere et al., 2006). However in our lab’s experience, preventing
substrate switching via activation of peroxisome proliferator-activated receptor alpha
(PPARα) exacerbates dysfunction in rat hearts subjected to pressure overload stress
(Young et al., 2001).
The uncoupling of glycolysis from glucose oxidation may be where the process
begins to unravel (Taegtmeyer, 2000). The lab has also demonstrated that myocardial
glucose uptake in excess of the oxidative capacity of the heart leads to contractile
dysfunction through the accumulation of glucose 6-phosphate, sustained activation of the
mammalian target of rapamycin (mTOR) and endoplasmic reticulum stress (Sen et al.,
2013).
A simple question is does induction of PKM2 allow the failing heart to respond to
uncertain nutrient and oxygen availability or does PKM2 exacerbate pathological
hypertrophy and adverse remodeling? I propose that PKM2 induction is part of the adaptive
response in the stressed heart. Unlike PKM1, which exists as a near-constitutively active
tetramer, PKM2 can exist as a dimer or tetramer and is uniquely subject to allosteric
regulation and various post-translational modifications that determine its function as
pyruvate kinase, protein kinase or transcription factor (Anastasiou et al., 2012; Wong et al.,
2013). Importantly, the ability of PKM2 to rapidly cycle between a tetramer and dimer could
be especially advantageous to the failing heart.

In its tetramer form, PKM2 acts as a

canonical pyruvate kinase, allowing pyruvate oxidation and ATP generation. The low
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catalytic activity of the dimer form slows glycolysis and allows for the redirection of glucosederived carbons into biosynthetic pathways promoting cell proliferation, in the case of
cancer, or, in the case of the heart, intracellular self-renewal and hypertrophy. It will be
important to determine if, similar to the Warburg effect in cancer, glucose-derived carbons
support cardiac hypertrophy.
It has also been proposed that “cellular oncogenes drive the progression to heart
failure” (Hoshijima and Chien, 2002). This is based on the observation that many of the
pathways driving tumor growth also drive cardiomyocyte hypertrophy (Cheng and Force,
2010; Mulvagh et al., 1988). Induction of PKM2 in the hypertrophying heart would fit with this
reasoning. Included in this original hypothesis was activation of the fetal gene, c-myc. In
cancer, c-myc drives the expression of three heterogeneous nuclear ribonucleoprotein
(hnRNP) proteins-polypyrimidine tract binding protein (PTB, also known as hnRNPI),
hnRNPA1 and hnRNPA2-that are essential for preferential splicing of PKM2 (David et al.,
2010). Because c-myc transcription was significantly induced in the sunitinib treated hearts
(Figure 4.2.6), it is possible that c-myc might also be important for preferential PKM2
splicing in the heart. Furthering this hypothesis, changes in hemodynamic load induces cmyc in the remodeling heart (Depre et al., 1998). As PKM2 expression seems to correlate
with hemodynamic load in the failing human heart (Figure 4.2.8), it seems likely that c-myc
plays a role in promoting PKM2 induction, though the exact mechanism awaits elucidation.
Hif1α and dysregulated c-myc have been shown to cooperatively promote transcription of
key glycolytic genes in cancer (Wong et al., 2013). However, in the adult heart, Hif1α and cmyc seem to play opposing roles. Whether these two factors cooperate in the failing heart,
or whether this is an anomaly of the sunitinib-treated heart, remains to be determined.
Vander Heiden and colleagues specifically deleted PKM2 in tumor cells by inserting
flox sites flanking exon 10 of the PKM gene. Cre-induced recombination led to selective
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expression of PKM1 and a nonfunctional, truncated version of the PKM gene, PKM-skip,
which included neither exon 9 or 10. Interestingly, PKM2 is not required for tumor formation
or progression. The obvious next experiment would be to delete PKM2 in the hearts of mice
exposed to pressure-overload stress. This would determine whether PKM2 induction is
adaptive or maladaptive feature of the stressed heart.
The reciprocal experiment would be to force PKM2 expression in the adult heart,
perhaps by using a conditional deletion of PKM1 in the adult heart. This would address the
“chicken or the egg” scenario with PKM2 expression and enhanced glucose uptake.
Christofk and colleagues have demonstrated that knockdown of PKM2 in cancer cell lines
decreased the rate of glycolysis and that reintroduction of PKM2 but not PKM1 enhanced
glycolysis and xenograft tumor formation (Christofk et al., 2008). PKM2 induction in the heart
is likely part of a coordinated response to hypoxic or hemodynamic stress in the heart.
Furthermore, PKM2 induction is probably not the cause of the glycolytic switch but rather an
important mediator.
PKM2 is subject to profound allosteric regulation and post-translational modifications
that regulate its function as a pyruvate kinase, protein kinase or transcription factor. These
nonmetabolic functions of PKM2 may be similarly important in the failing heart. For instance,
oxidation of cysteine 358 decreases PKM2 activity, leading to a redirection of glucose into
the pentose phosphate pathway and generation of reducing equivalents. Dimeric PKM2 can
also translocate into the nucleus, for instance in response to EGFR stimulation, and
transactivate transcription factors such as β-catenin or the stem cell factor Oct4 (Lee et al.,
2008; Yang et al., 2011). PKM2 can use the high energy bonds from PEP to phosphorylate
and activate proteins such as Stat3 (Gao et al., 2012). Stat3 is important for proper function
of the electron transport chain (Wegrzyn et al., 2009), and cardiomyocyte-specific knockout
of Stat3 accelerates inflammation-induced cardiac fibrosis (Jacoby et al., 2003).
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Several small molecule activators of PKM2 have been developed and have proven to
suppress tumor growth (Anastasiou et al., 2012; Parnell et al., 2013). Similar to the
endogenous activator of PKM2, fructose-1,6-bisphopsphate (FBP), these molecules, namely
DASA-58 (N, N′-diarylsulfonamide, NCGC001859) and TEPP-46 (thieno-[3,2-b]pyrrole [3,2d]pyridazinone, NCGC00186528), stabilize the high-activity tetramer conformation of PKM2
allowing for flow of glucose through to pyruvate (Wong et al., 2013). Phosphorylation of
tyrosine 105 by fibroblast growth factor receptor 1 (FGFR1) leads to FBP dissociation and
destabilization of the tetramer formation. Importantly, small molecule activators of PKM2 that
bind to this same FBP binding pocket are resistant to this phosphorylation (Wong et al.,
2013). More recently small molecule activators of PKM2 have been developed which bind to
a distinct site from FBP and appear to be more effective (Anastasiou et al., 2012). The
question remains whether stabilization of PKM2 tetramer formation would be advantageous
to the failing heart by better matching glucose uptake and oxidation. Forced fatty acid
oxidation (i.e. activation of PPARs with fenofibrate (Chicco et al., 2007) exacerbates
dysfunction in the failing heart. It is unclear whether normalization of PKM2 function in the
failing heart would be similarly detrimental. It is important to note that while these activators
restore the pyruvate kinase activity of PKM2, the potentially advantageous nuclear signaling
and protein kinase activities are lost. Thus these inhibitors may be a useful tool to delineate
the two function of PKM2 in the heart.
To my knowledge, this is the first evidence of PKM2 induction in any model of heart
failure. The importance of secondary pathways of glucose metabolism in the heart is largely
unrecognized beyond glycogen as an energetic store and redirection of glucose into the
pentose phosphate pathways to maintain redox status in the failing heart (Doenst et al.,
2013). PKM2 induction may be just the tip of the Warburg Effect iceberg in the failing heart.
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Figure 4.2.9.

Figure 4.2.9. Summary. In the failing heart, activation of the hypoxia response factor HIf1α
HIf1
results in induction of the M2 isoform of pyruvate kinase. This leads to a redirection of
glycose into secondary pathways of metabolism including lactate production, glycogen
accumulation on O-GlcNAcylation
GlcNAcylation of proteins.
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Chapter 5
CONCLUDING REMARKS AND FUTURE DIRECTIONS
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5.1 Summary of findings
In my work, I explored mechanisms of cardiotoxicity due to the cancer
chemotherapeutic agent, the receptor tyrosine kinase inhibitor sunitinib. My two major
finding are that sunitinib denudes the coronary vasculature of an important constituent, its
pericytes, and that sunitinib induces major metabolic changes in the heart which are
consistent with metabolic and structural remodeling of the cardiomyocyte. I will now discuss
the importance of my findings and how my findings may relate to each other.
Coronary microvascular pericytes are a primary target of sunitinib-induced
cardiotoxicity. Work in my previous lab demonstrated that inhibition of the essential
prosurvival signal, PDGFRβ, leads to cell death and coronary microvascular dysfunction. As
I will discuss in detail below, microvascular dysfunction is associated with myocardial
hypoxia and with the induction of the fetal gene program. My further work focused on
sunitinib-induced metabolic changes in the heart and resulted in the discovery of an
additional member of the fetal gene program, the M2 isoform of pyruvate kinase (PKM2).
Most importantly, PKM2 induction is a signature of not only sunitinib cardiotoxicity but is also
a striking feature of the failing human heart. To my knowledge, this is the first evidence of
PKM2 induction in any model of heart failure.
This work began with the fact that cardiotoxicity due to cancer treatments is a major
obstacle in effective cancer treatment. A patient may outlive his or her cancer only to
succumb to heart failure in as little as five years (Go et al., 2013; Levy et al., 2002). The
focus of my dissertation was therefore twofold: First, to elucidate the mechanism of sunitinibinduced cardiotoxicity in order to develop a cardioprotective strategy in patients receiving
sunitinib and, secondly, to use sunitinib-induced cardiotoxicity as a tool to identify novel
pathways that contribute to the progression of heart failure. I have demonstrated success in
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both areas. Thalidomide, or perhaps one of its derivatives, may prove to be a viable
treatment for patients at high risk of developing cardiac dysfunction while receiving sunitinib.
Possible mechanisms for this protective effect are discussed in Chapter 3. Additionally,
PKM2 may represent a novel metabolic target for the treatment of heart failure, although it
remains to be determined whether the upregulation of PKM2 is adaptive or maladaptive to
cardiac stress (discussed in Chapter 4).
The data presented here reveal two important things. First, microvascular pericytes
are essential to maintain cardiac function in response to stress. This adds to a growing body
of evidence suggesting that the coronary vasculature is more dynamic than previously
recognized, reviewed by (Feigl, 1983) and (Gould et al., 2013). Secondly, PKM2 may be an
important mediator of cardiac energy provision. However, the extent to which the Warburg
Effect exists in the heart remains to be determined. The relevance of these two observations
to non-chemotherapy related heart failure is still to be proven and beyond the scope of my
thesis. Clearly, more work is necessary to elucidate the mechanisms driving these two
observations. Particular areas of future work are discussed below.

5.2 Does pericyte loss result in myocardial hypoxia?
One of my most important observations was establishing the fact that sunitinib
treatment alone does not induce PKM2 expression in isolated adult cardiomyocytes (Figure
4.2.7). This suggests that PKM2 induction through Hif1α may be secondary to the depletion
of pericytes. In support of this hypothesis, deletion of either PDGF-B or PDGFRβ results in
pericyte loss and leads to impaired perfusion and tissue hypoxia in the developing mouse
brain (Hellström et al., 2001). Pericyte loss also leads to tissue hypoxia in a model of
ischemic retinopathy (Wilkinson-Berka et al., 2004) and hypoxia-associated epithelial-to119

mesenchymal transition and increased metastasis was linked to pericyte loss in a mouse
model of breast cancer (Cooke et al., 2012). Collectively, these studies demonstrate that
pericyte loss can lead to tissue hypoxia, and my results now suggest the same may be true
for the heart.
To induce deletion of pericytes in the breast tumors, the group of Cook et al.
employed an inventive strategy, which could be used to determine whether PKM2 induction
is secondary to pericyte loss and hypoxia in the heart (Cooke et al., 2012). The NG2 and,
separately, PDGFRβ promoter was used to drive expression of the viral thymidine kinase
(TK) in pericytes. Subsequent treatment with the antiviral drug ganciclovir led to selective
cell death in TK-expressing cells, due to the fact that viral TK converts the nontoxic
ganciclovir into a toxic metabolite (Barese et al., 2012). This approach may be
advantageous over traditional methods that induce pericyte cell death, such as deletion of
PDGF-B or PDGFRβ because the TK-ganciclovir approach would avoid the use of a Cre
recombinase, which can be cardiotoxic at high levels (Buerger et al., 2006).
Thalidomide co-treatment may also be a useful tool to determine whether PKM2
induction is secondary to pericyte loss. In the first part of my thesis, I demonstrated that
thalidomide can restore pericyte coverage. Thus, if protection of microvascular pericytes
with thalidomide is sufficient to prevent induction of PKM2, it may be concluded that pericyte
loss leads to PKM2 induction. However, there are several issues with this approach,
particularly the non-specific nature of both sunitinib and thalidomide. Therefore a genetic
approach, such as the TK-ganciclovir approach described above, would yield a more
definitive answer, and I did not pursue this line of research.
In addition to the regulation of capillary diameter (discussed in chapter 3), the
diffusion distance that oxygen much travel from its dissociation from hemoglobin, across the
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endothelium and finally to the mitochondria is crucially important in determining oxygen
levels within the cell. This is illustrated by the Krogh cylinder model, which relates the radius
of a capillary to the radius of a theoretical cylinder of tissue to which it supplies oxygen
(Figure 5.1) (Fishman, 1982). The ratio of the cross-sectional area of the capillary to the
cross-sectional area of the cylinder is directly proportional to the decrease in oxygen
pressure from the capillary to that point. For example in Figure 5.1, a cell 10 units away
from a capillary that has a radius of 5 units results in a ratio of 1:4. Therefore, if the arterial
pO2 is 80 mmHg, the pO2 at that cell would be 20 mmHg. However if this distance is
doubled, the pO2 at the level of the cell would only be 5 mmHg, which would be sufficient to
induce Hif1α activation.
In my model of sunitinib-induced pericyte loss, this distance may increase due to
interstitial edema resulting from increased vessel leakiness (Figure 3.2.6). Although it does
not likely double, the extent of interstitial edema was not measured in my experiments. It is
also important to stress that the pO2 within the capillary does not remain constant along the
length of the capillary. As oxygen is extracted by the tissue the intracapillary pO2 declines.
This, coupled to decreased oxygen gradients at more distal sites and turbulent flow, would
suggest that there are areas within the sunitinib treated heart where the pO2 falls to critically
low levels.
The existence of hypoxia in vivo is prohibitively difficult to prove. Precise
measurement of cellular PO2 with an oxygen electrode is the definitive method to establish
the presence of hypoxia (Krogh, 1919a, b). However, this is not always technically possible.
Hypoxyprobe (pimonidazole HCl) is a commercially available tracer that can be used to label
hypoxic areas in vivo (Hypoxyprobe, NPI Inc., Burlington, MA). Pimonidazole is stabilized
under hypoxic conditions and binds to peptide thiols such as glutathione (Hodgkiss, 1998).
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Figure 5.1

Figure 5.1. The Krogh cylinder model of an oxygen pressure field. The pO2 at a given
distance (R) from the capillary is directly proportional to the ratio of the capillary crosssectional area to the cross-sectional area of the theoretical cylinder to which it supplies
oxygen. For instance, at a point that is 10 units from a capillary that has a radius of 5 units
results in a ratio of 1 to 4. Thus, if the capillary has a pO2 of 80mmHg, the pO2 at that point
would be 20mmHg. Source: B. J. McGuire , T. W. Secomb. (1985) A theoretical model for
oxygen transport in skeletal muscle under conditions of high oxygen demand. J Appl.
Physiol. Reused with permission from the journal.
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Fixed tissue sections or tissue lysates can then be probed with an antibody directed against
pimonidazole. My attempt to use this probe in my sunitinib-treated mice resulted in falsepositive staining in my control mice, perhaps due to incomplete washout of the probe before
sacrifice. I therefore decided to abandon this approach.
Another approach could be to use positron emission tomography (PET) imaging with
18

F-fluoromisonidazole (Rasey et al., 1996). Similar to pimonidazole, fluoromisonidazole is

stabilized under hypoxic conditions and has been used to image hypoxic regions in both
human and mouse tumors (Bentzen et al., 2002; Rajendran et al., 2004). Use of this probe
in sunitinib treated mice or in conjunction with a model of pericyte loss, such as the TKganciclovir approach suggested above, would help establish whether pericyte loss results in
myocardial hypoxia.
Still, it is entirely possible that sunitinib treatment leads to Hif1α stabilization
irrespective of a change in cellular PO2. Sustained mTOR activation through loss of TSC2
has been shown to stabilize Hif1α and induce PKM2 expression in mouse kidney tumors
(Sun et al., 2011). Similarly, preliminary evidence from my lab indicates that conditional
deletion of tuberous sclerosis 2 (TSC2), and therefore activation of mTOR, in the adult heart
leads to PKM2 induction (Davogustto, unpublished observations). Additionally, oleanolic
acid has been shown to repress PKM2 expression in isolated cancer cell lines (Liu et al.,
2014). In addition to inducing pressure overload stress (discussed in Chapter 4), it will be
interesting to determine whether other mechanisms, such as mTOR activation or metabolic
stress, can induce PKM2 in the heart.

5.3 Sunitinib as an insulin sensitizing agent.
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The induction of PKM2 is not likely the cause of enhanced systemic insulin sensitivity
during sunitinib treatment. As discussed in the previous chapter, it has been proposed that
sunitinib decreases blood glucose levels though preservation of pancreatic beta cells
(Hagerkvist et al., 2008; Han et al., 2009; Louvet et al., 2008). However, sunitinib also
reduces blood glucose levels in both non-diabetic mice and in humans (Billemont et al.,
2008; Breccia et al., 2005; Breccia et al., 2004; Louvet et al., 2008; Mokhtari and Welsh,
2010; Templeton et al., 2008; Tsapas et al., 2008; Veneri et al., 2005). Therefore, it seems
likely that sunitinib increases peripheral insulin sensitivity. In normal insulin responsive cells,
such as cardiomyocytes, activation of the PI3K-Akt signaling cascade by the binding of
insulin to the insulin receptor leads to increased glucose uptake though trafficking of glucose
transporters (primarily GLUT4) to the cell surface (James et al., 1989). However, similar to
the VEGFRs and PDGFRs, the insulin receptor is a receptor tyrosine kinase, making it
unlikely that sunitinib would increase insulin sensitivity through activation of the insulin
receptor. However sunitinib may alter increase GLUT4 translocation or inhibit its endocytosis
from the plasma membrane (Martin et al., 1999).
In the treatment of diabetes, enhanced insulin sensitivity is achieved through
pharmacological modulation of several pathways. The group of insulin-sensitizing agents
known as thiazolidinediones (TZDs), improve insulin sensitivity by lowering plasma free fatty
acids and activating peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ
regulates the expression of multiple metabolic enzymes (Spiegelman, 1998). In rats, the
TZD rosiglitazone increases GLUT4 expression (Oakes et al., 1994). Therefore, modulation
of PPARγ could be a mechanism by which sunitinib increases insulin sensitivity.
Metformin also increases insulin sensitivity in the peripheral tissues. This is achieved
primarily though decreasing hepatic gluconeogenesis (Stumvoll et al., 1995). However,
metformin also activates AMP-activated protein kinase (AMPK) (Zhou et al., 2001a) and has
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been shown to increase glucose uptake in vitro (Bertrand et al., 2006). Conversely, sunitinib
may directly inhibit AMPK (Kerkela et al., 2009; Laderoute et al., 2010). Sunitinib treatment
is also associated with increased hepatic glucose production, as measured during the
hyperinsulinemic euglycemic clamp procedure (Figure 4.2.2). Therefore, it is not likely that
sunitinib enhances insulin sensitivity in a manner similar to metformin.
It is, however, possible that sunitinib-induced pericyte loss directly enhances insulin
sensitivity. The laboratory of Alan Attie at The University of Wisconsin-Madison has
suggested that pericyte loss leads to increased transendothelial transport of insulin, allowing
enhanced delivery of insulin to the muscle cell (Raines et al., 2011; Richards et al., 2010). In
support of this hypothesis, pericyte loss in a rat model of diabetic retinopathy is associated
with increased expression of genes involved in vesicular transport such as caveolin-1 and
plasmalemmal vesicle associated protein-1 (PV-1) (Klaassen et al., 2009).
Alternatively, because sunitinib is a highly promiscuous kinase inhibitor, it’s entirely
possible that a unique combination of kinase inhibition leads to enhanced insulin sensitivity
and glucose uptake in the sunitinib-treated animal. For this reason, I suspect that a
proteomic approach would be useful to elucidate the mechanism of enhanced insulin
sensitivity associated with sunitinib treatment. This is, however, beyond the scope of my
thesis.

5.4. Why do only a fraction of sunitinib-treated patients develop cardiac dysfunction?
A vexing question is why only approximately 20% of patients develop cardiac
dysfunction while on sunitinib. Assuming sunitinib also induces pericyte loss in humans,
what is unique about the vasculature of these patients that makes them sensitive to
sunitinib? Interestingly, patients who develop hypertension while receiving sunitinib have
125

significantly better responses to treatment and longer progression-free survival, suggesting
that there is something different about the vasculature of these patients (Bono et al., 2011;
Rini et al., 2011)). Yet the question remains, how do we determine what that difference is,
and how can it be used to better inform treatment strategies?
This question is of course not limited to sunitinib cardiotoxicity. Predicting whether a
patient will respond to a given treatment spans all avenues of human disease and is the
foundation of personalized medicine. My previous lab attempted to answer a similar
question: what determines the time of transplant-free survival in a patient with new onset
non-ischemic cardiomyopathy. That is, what determines whether a patient will remain stable
for some time or will rapidly decompensate, in need of mechanical assist and/or need
cardiac transplantation. By performing microRNA profiling on endomyocardial biopsies
obtained from a small number of patients (10), my previous lab found that differential
regulation of three microRNAs was predictive of outcome (unpublished data). Similarly, my
current lab found that lower expression of two microRNAs, miRs 23a and 195, was
associated with functional recovery in patients placed on a LVAD compared to patients who
remained LVAD-dependent (Ramani et al., 2011). However, other tools may be more
predictive of the development of cardiac dysfunction with sunitinib such as proteomics or
epigenetic analysis. None of this has been attempted as yet.
5.5. Future Directions
My dissertation work revealed two important new findings: the necessity of
microvascular pericyte coverage in preserving cardiac function and the induction of PKM2 in
the failing heart. Sunitinib cardiotoxicity is, admittedly, not a robust model of heart failure
because, due to the nonspecific nature of the drug, the mechanisms driving certain
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observations are difficult to discern. Furthermore, it is unclear whether inhibition of these
pathways is relevant to other models of heart failure.
Irrespective of any mechanisms, my findings indicate extensive remodeling of the
heart, akin to the remodeling observed in cancer cells. In cancer cells, glucose metabolism
is redirection from oxidation, and to some extent also from glycolysis, to a host of
biosynthetic pathways including the pentose phosphate pathway (Figure 5.2) and reviewed
by (Vander Heiden et al., 2009). Increased flux through the pentose phosphate provides
reducing equivalents (NADPH) and precursors for nucleotide synthesis (ribose) and
nonessential amino acids, both of which are necessary for cell growth and division.
Furthermore, the increased reliance on glutamine by cancer cells leads to production of
acetyl-CoA for lipid biosynthesis via cycling through citrate. Mutations in key regulators of
these pathways, such as in LKB1, p53 and c-myc, enable cancer cells to redirect glucose
and glutamine into these biosynthetic pathways and proliferate uncontrollably.
The main difference between the Warburg Effect in cancer and in the heart is that
cancer cells hypertrophy and proliferate (Vander Heiden et al., 2009) while heart muscle
cells hypertrophy and fail (Sen et al., 2013). However the pathways driving cellular
hypertrophy in both cases may be very much the same. In addition to providing a more
efficient fuel source, the switch to predominant glucose metabolism in the stressed heart
may also support hypertrophy. The Warburg Effect may not be entirely applicable to the
hypoxic heart, such as in the case of sunitinib cardiotoxicity, because it seems unlikely that
the heart would synthesize new proteins under conditions of limited oxygen availability.
However, increased O-GlcNAcylation of proteins may be part of the hypoxic response.
Increased hexosamine and protein O-GlcNAcylation is protective in the setting of ischemiareperfusion (Jensen et al., 2012). Nonetheless, in response to other stresses such as
pressure overload or even exercise, the Warburg Effect may be a previously unrecognized
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Figure 5.2

Figure 5.2. The Warburg Effect in cancer cells. The Warburg Effect is controlled by
pathways involving known oncogenes and tumor suppressors. [Source: Vander Heiden,
M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg Effect: The
Metabolic Requirements of Cell Proliferation. Science 324, 1029-1033. (Vander Heiden et
al., 2009), reprinted with permission from the AAAS].
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mechanism through which the heart obtains carbons and reducing equivalents for cardiac
hypertrophy.
An important future experiment would be to trace glucose-derived carbons during
pressure overload induced hypertrophy. The specifics of this experiment would be difficult to
perform in vivo because cardiac hypertrophy requires at least a couple of weeks. It might be
possible to introduce [U-13C]glucose into the chow of mice that have undergone transverse
aortic banding. However, analysis of these findings may be confounded by the dynamic
nature of protein turnover in the heart (Razeghi et al., 2003). Examination of the Warburg
Effect in cancer does not have this problem because cancer cells rapidly proliferate in
culture. As little as 6 hours of incubation with [U-13C]glucose or [U-13C]glutamine was
sufficient to trace the incorporation of these carbons into biosynthetic pathways via gas
chromatography-mass spectrometry (Mullen et al., 2012). A similar experiment could be
performed in cultured cardiomyocytes. Cultured neonatal rat cardiomyocytes hypertrophy in
response to norepinephrine (Simpson, 1983; Simpson, 1985). However as my work has
demonstrated, neonatal rat cardiomyocytes already express PKM2, a hallmark of the
Warburg Effect (Figure 4.2.7). Therefore, this experiment would need to be performed in
isolated adult cardiomyocytes. Stimulation of isolated adult feline cardiomyocytes with TNFα is sufficient to induce hypertrophy (Yokoyama et al., 1997) and therefore these
experiments are feasible. Additionally, the Warburg Effect is highly reliant on glutamine for
citrate and acetyl-CoA for the synthesis of fatty acids (Mullen et al., 2012). Future
experiments evaluating the Warburg Effect in the hypertrophying heart may also focus on
glutamine metabolism.
Assuming that glucose- or glutamine-derived carbons support cardiac hypertrophy,
the next step would be to determine the mechanisms driving this effect. For instance, our lab
has demonstrated that sustained activation of mTOR leads to uncontrolled protein synthesis
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and endoplasmic reticulum stress in the heart (Sen et al., 2013). Based on these findings,
we developed mice in which the negative regulator of mTOR, TSC2, can be conditionally
deleted. Preliminary evidence suggests that this leads to an induction of PKM2 in the heart.
AMPK may also mediate the Warburg Effect. As my lab has shown, AMPK regulated protein
turnover through the E3 ligases Atrogin-1 and MuRF1 (Baskin and Taegtmeyer, 2011).
Finally, as discussed in Chapter 4, I also predict that c-myc plays an important role in
mediating the Warburg Effect in the heart. It will be interesting to determine if driving c-myc
expression in the heart is sufficient to induce the Warburg Effect in the heart.
Further work will determine how these findings will be leveraged for the development
of novel treatments for human heart failure. At this point, there are certainly more questions
than answers. Yet, in the words of Albert Einstein, “scientific endeavor is a natural whole the
parts of which mutually support one another in a way which, to be sure, no one can
anticipate” (Einstein, 2011).
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Figure 5.3

Figure 5.3 Summary of findings.
Sunitinib induces microvascular pericyte loss through inhibition of the platelet derived growth
factor receptor beta (PDGFR
(PDGFRβ), resulting in microvascular dysfunction and myocardial
hypoxia.. Subsequent activation of hypoxia inducible factor 1 alpha (Hif1α) leads to induction
of the M2 isoform of pyruvate kinase (PKM) and switch to predo
predominant
minant glycolysis and a
redirection of glucose-derived
derived carbons into bio
bio. PEP, phosphoenolpyruvate; PPP, pentose
phosphate pathway; O-GlcNAc
GlcNAc, O-Linked β-N-acetylglucosamine.
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